Chemed
CHE
#2967
Rank
$5.32 B
Marketcap
$377.57
Share price
-0.05%
Change (1 day)
-38.82%
Change (1 year)
Chemed Corporation is an American company that provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

Chemed - 10-Q quarterly report FY2013 Q2


Text size:
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

(Mark One)

x    Quarterly Report Under Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2013

o    Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission File Number: 1-8351

CHEMED CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
31-0791746
(State or other jurisdiction of incorporation or
organization)
 
(IRS Employer Identification No.)
255 E. Fifth Street, Suite 2600, Cincinnati, Ohio
45202
(Address of principal executive offices)
(Zip code)
 
(513) 762-6500
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
 
Yes
x
 
No
o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
 
Yes
x
 
No
o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act).
 
Large accelerated
filer
x
Accelerated
filer
o
 
Non-accelerated
filer
o
 
Smaller reporting
company
o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
 
Yes
o
 
No
x

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class
Amount
Date
     
Capital Stock $1 Par Value
18,656,125 Shares
June 30, 2013

 
 

 
- 1 -

 

CHEMED CORPORATION AND
SUBSIDIARY COMPANIES



Index

   
   
 
Page No.
 
 
 
3
   
 
4
   
 
5
   
6
   
18
   
35
   
35
   
 
35
   
35
   
36
   
36
   
36
   
36
   
36
EX – 31.1
 
EX – 31.2
 
EX – 31.3
 
EX – 32.1
 
EX – 32.2
 
EX – 32.3
 
EX – 101.INS
 
EX – 101.SCH
 
EX – 101.CAL
 
EX – 101.DEF
 
EX – 101.LAB
 
EX – 101.PRE
 
 
 
- 2 -

 

PART I. FINANCIAL INFORMATION
 
Item 1. Financial Statements
 
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
 
UNAUDITED CONSOLIDATED BALANCE SHEET
 
(in thousands, except share and per share data)
 
        
        
   
June 30,
  
December 31,
 
   
2013
  
2012
 
ASSETS
      
Current assets
      
Cash and cash equivalents
 $113,047  $69,531 
Accounts receivable less allowances of $12,221 (2012 - $10,892)
  76,356   93,333 
Inventories
  6,156   7,058 
Current deferred income taxes
  19,322   13,659 
Prepaid income taxes
  4,911   2,643 
Prepaid expenses
  13,518   11,447 
Total current assets
  233,310   197,671 
Investments of deferred compensation plans
  40,583   36,089 
Properties and equipment, at cost, less accumulated depreciation of $174,602 (2012 - $164,607)
  90,229   91,934 
Identifiable intangible assets less accumulated amortization of $31,212 (2012 - $30,414)
  57,348   57,177 
Goodwill
  466,271   465,832 
Other assets
  11,137   10,923 
Total Assets
 $898,878  $859,626 
          
LIABILITIES
        
Current liabilities
        
Accounts payable
 $35,921  $48,472 
Current portion of long-term debt
  179,154   - 
Income taxes
  4,561   4,938 
Accrued insurance
  42,616   40,654 
Accrued compensation
  42,156   45,457 
Other current liabilities
  33,840   17,301 
Total current liabilities
  338,248   156,822 
Deferred income taxes
  27,981   27,662 
Long-term debt
  -   174,890 
Deferred compensation liabilities
  39,660   35,599 
Other liabilities
  11,702   11,362 
Total Liabilities
  417,591   406,335 
          
STOCKHOLDERS' EQUITY
        
Capital stock - authorized 80,000,000 shares $1 par; issued 32,074,611 shares (2012 - 31,589,366 shares)
  32,075   31,589 
Paid-in capital
  466,980   437,364 
Retained earnings
  653,146   623,035 
Treasury stock - 13,515,437 shares (2012 - 13,057,270)
  (673,008)  (640,732)
Deferred compensation payable in Company stock
  2,094   2,035 
Total Stockholders' Equity
  481,287   453,291 
Total Liabilities and Stockholders' Equity
 $898,878  $859,626 
  
See accompanying notes to unaudited consolidated financial statements.
 
 
 
- 3 -

 

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
 
UNAUDITED CONSOLIDATED STATEMENT OF INCOME
 
(in thousands, except per share data)
 
              
              
              
   
Three Months Ended June 30,
  
Six Months Ended June 30,
 
   
2013
  
2012
  
2013
  
2012
 
Service revenues and sales
 $357,198  $354,170  $723,839  $707,113 
Cost of services provided and goods sold (excluding depreciation)
  255,359   257,368   519,666   514,813 
Selling, general and administrative expenses
  53,107   49,770   108,667   102,937 
Depreciation
  6,899   6,380   13,694   12,621 
Amortization
  1,181   1,127   2,308   2,240 
Other operating expenses
  14,760   -   14,760   - 
Total costs and expenses
  331,306   314,645   659,095   632,611 
Income from operations
  25,892   39,525   64,744   74,502 
Interest expense
  (3,697)  (3,672)  (7,791)  (7,289)
Other income - net
  1,696   (970)  3,402   1,125 
Income before income taxes
  23,891   34,883   60,355   68,338 
Income taxes
  (9,283)  (13,609)  (23,469)  (26,619)
Net income
 $14,608  $21,274  $36,886  $41,719 
                  
                  
Earnings Per Share
                
Net income
 $0.79  $1.12  $1.99  $2.20 
Average number of shares outstanding
  18,606   18,998   18,564   18,976 
                  
Diluted Earnings Per Share
                
Net income
 $0.77  $1.10  $1.94  $2.16 
Average number of shares outstanding
  18,966   19,369   18,980   19,357 
                  
Cash Dividends Per Share
 $0.18  $0.16  $0.36  $0.32 
                  
See accompanying notes to unaudited consolidated financial statements.
 
 
 
- 4 -

 

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
 
UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS
 
(in thousands)
 
        
   
Six Months Ended
 
   
June 30,
 
   
2013
  
2012
 
Cash Flows from Operating Activities
      
Net income
 $36,886  $41,719 
Adjustments to reconcile net income to net cash provided
        
by operating activities:
        
Depreciation and amortization
  16,002   14,861 
Deferred income taxes
  (5,375)  (4,895)
Provision for uncollectible accounts receivable
  5,432   4,730 
Amortization of discount on convertible notes
  4,264   3,985 
Stock option expense
  3,103   4,312 
Noncash long-term incentive compensation
  1,106   - 
Changes in operating assets and liabilities, excluding
        
amounts acquired in business combinations:
        
Decrease/(increase) in accounts receivable
  11,745   (8,543)
Decrease in inventories
  902   522 
Decrease/(increase) in prepaid expenses
  (2,017)  672 
Increase/(decrease) in accounts payable and other current liabilities
  14,721   (3,593)
Decrease in income taxes
  (409)  (1,029)
Increase in other assets
  (4,914)  (2,283)
Increase in other liabilities
  4,401   4,493 
Excess tax benefit on share-based compensation
  (2,478)  (1,069)
Other sources
  1,297   773 
Net cash provided by operating activities
  84,666   54,655 
Cash Flows from Investing Activities
        
Capital expenditures
  (12,200)  (18,474)
Business combinations, net of cash acquired
  (1,501)  (1,500)
Other sources
  101   357 
Net cash used by investing activities
  (13,600)  (19,617)
Cash Flows from Financing Activities
        
Purchases of treasury stock
  (18,448)  (11,138)
Dividends paid
  (6,775)  (6,160)
Capital stock surrendered to pay taxes on stock-based compensation
  (4,269)  (1,645)
Proceeds from exercise of stock options
  12,558   3,670 
Excess tax benefit on share-based compensation
  2,478   1,069 
Increase/(decrease) in cash overdrafts payable
  (11,608)  985 
Debt issuance costs
  (1,104)  - 
Other sources/(uses)
  (382)  66 
Net cash used by financing activities
  (27,550)  (13,153)
Increase in Cash and Cash Equivalents
  43,516   21,885 
Cash and cash equivalents at beginning of year
  69,531   38,081 
Cash and cash equivalents at end of period
 $113,047  $59,966 
          
See accompanying notes to unaudited consolidated financial statements.
 
 
 
- 5 -

 
 
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
Notes to Unaudited Consolidated Financial Statements

1.     Basis of Presentation

As used herein, the terms "We," "Company" and "Chemed" refer to Chemed Corporation or Chemed Corporation and its consolidated subsidiaries.

We have prepared the accompanying unaudited consolidated financial statements of Chemed in accordance with Rule 10-01 of SEC Regulation S-X.  Consequently, we have omitted certain disclosures required under generally accepted accounting principles in the United States (“GAAP”) for complete financial statements. The December 31, 2012 balance sheet data were derived from audited financial statements but do not include all disclosures required by GAAP.  However, in our opinion, the financial statements presented herein contain all adjustments, consisting only of normal recurring adjustments, necessary to present fairly our financial position, results of operations and cash flows.  These financial statements are prepared on the same basis as and should be read in conjunction with the Consolidated Financial Statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2012.

2.     Revenue Recognition

Both the VITAS segment and the Roto-Rooter segment recognize service revenues and sales when the earnings process has been completed.  Generally, this occurs when services are provided or products are delivered.  VITAS recognizes revenue at the estimated realizable amount due from third-party payers.  Medicare payments are subject to certain limitations, as described below.

As of June 30, 2013, VITAS has approximately $1.0 million in unbilled revenue included in accounts receivable (December 31, 2012 - $457,000).  The unbilled revenue at VITAS relates to hospice programs currently undergoing various patient file reviews.  Surveyors working on behalf of the U.S. Federal government review certain patient files for compliance with Medicare regulations.  During the time the patient file is under review, we are unable to bill for care provided to those patients.  We make appropriate provisions to reduce our accounts receivable balance for any governmental or other payer reviews resulting in denials of patient service revenue.  We believe our hospice programs comply with all payer requirements at the time of billing.  However, we cannot predict whether future billing reviews or similar audits by payers will result in material denials or reductions in revenue.

We actively monitor each of our hospice programs, by provider number, as to their specific admission, discharge rate and median length of stay data in an attempt to determine whether they are likely to exceed the annual per-beneficiary Medicare cap (“Medicare cap”).  Should we determine that revenues for a program are likely to exceed the Medicare cap based on projected trends, we attempt to institute corrective action to influence the patient mix or to increase patient admissions.  However, should we project our corrective action will not prevent that program from exceeding its Medicare cap, we estimate the amount of revenue recognized during the period that will require repayment to the Federal government under the Medicare cap and record the amount as a reduction to patient revenue.

During the three and six month periods ended June 30, 2013, we reversed Medicare cap liability for amounts recorded in the fourth quarter of 2012 for three programs’ projected 2013 measurement period liability.  We reversed these amounts as improving admissions trends in these programs indicate that the liability had been eliminated.  During the second quarter of 2013 this reversal was partially offset by an $855,000 Medicare cap liability for one program’s projected 2013 measurement period liability.

Shown below is the Medicare cap liability activity for the periods ended (in thousands):

        
    
   June 30, 
   
2013
 
2012
 
Beginning balance January 1,
 $1,261  $2,965 
2013 measurement period
  (18)  - 
2012 measurement period
  -   (2,577)
Ending balance June 30,
 $1,243  $388 
 
 
- 6 -

 
 
Vitas provides charity care, in certain circumstances, to patients without charge when management of the hospice program determines, at the time services are performed, that the patient does not have the financial wherewithal to make payment.  There is no revenue or associated accounts receivable in the accompanying consolidated financial statements related to charity care.  The cost of charity care is calculated by taking the ratio of charity care days to total days of care and multiplying by total cost of care.  The cost of charity care is as follows (in thousands):
   
Three months ended June 30,
 
Six months ended June 30,
2013
 
2012
 
2013
 
2012
$1,955 $1,789 $3,884 $4,038

3.     Segments

Service revenues and sales and after-tax earnings by business segment are as follows (in thousands):

   
Three months ended June 30,
  
Six months ended June 30,
 
   
2013
  
2012
  
2013
  
2012
 
Service Revenues and Sales
    
 
     
 
 
VITAS
 $263,568  $265,213  $534,895  $526,060 
Roto-Rooter
  93,630   88,957   188,944   181,053 
Total
 $357,198  $354,170  $723,839  $707,113 
                  
After-tax Earnings
                
VITAS
 $20,485  $20,433  $40,628  $40,060 
Roto-Rooter
  1,414   8,074   11,038   15,569 
Total
  21,899   28,507   51,666   55,629 
Corporate
  (7,291)  (7,233)  (14,780)  (13,910)
Net income
 $14,608  $21,274  $36,886  $41,719 

We report corporate administrative expenses and unallocated investing and financing income and expense not directly related to either segment as “Corporate”.

4.     Earnings per Share

Earnings per share (“EPS”) are computed using the weighted average number of shares of capital stock outstanding.  Earnings and diluted earnings per share are computed as follows (in thousands, except per share data):

       
Net Income
For the Three Months Ended June 30,
 
Income
   
Shares
  
Earnings per
Share
2013
                  
 
Earnings
 
$
 14,608
   
 18,606
  
$
 0.79
 
Dilutive stock options
   
 -
   
 267
     
 
Nonvested stock awards
   
 -
   
 93
     
 
Diluted earnings
 
$
 14,608
   
 18,966
  
$
 0.77
                    
2012
                  
 
Earnings
 
$
 21,274
   
 18,998
  
$
 1.12
 
Dilutive stock options
   
 -
   
 288
     
 
Nonvested stock awards
   
 -
   
 83
     
 
Diluted earnings
 
$
 21,274
   
 19,369
  
$
 1.10
 
 
- 7 -

 
 
       
Net Income
For the Six Months Ended June 30,
 
Income
   
Shares
  
Earnings per
Share
2013
                  
 
Earnings
 
$
 36,886
   
 18,564
  
$
 1.99
 
Dilutive stock options
   
 -
   
 316
     
 
Nonvested stock awards
   
 -
   
 100
     
 
Diluted earnings
 
$
 36,886
   
 18,980
  
$
 1.94
                    
2012
                  
 
Earnings
 
$
 41,719
   
 18,976
  
$
 2.20
 
Dilutive stock options
   
 -
   
 294
     
 
Nonvested stock awards
   
 -
   
 87
     
 
Diluted earnings
 
$
 41,719
   
 19,357
  
$
 2.16

For the three and six-month periods ended June 30, 2013, 31,000 stock options were excluded from the computation of diluted earnings per share because they would have been anti-dilutive. For the three and six-month period ended    June 30, 2012, 1.4 million stock options were excluded from the computation of diluted earnings per share.

Diluted earnings per share may be impacted in the future as the result of the issuance of our 1.875% Senior Convertible Notes (the “Notes”) and related purchased call options and sold warrants.  Per FASB’s authoritative guidance on the effect of contingently convertible instruments on diluted earnings per share and convertible bonds with an issuer option to settle for cash upon conversion, we will not include any shares related to the Notes in our calculation of diluted earnings per share until our average stock price for a quarter exceeds the current conversion price.  We would then include in our diluted earnings per share calculation those shares issuable using the treasury stock method.  The amount of shares issuable is based upon the amount by which the average stock price for the quarter exceeds the conversion price.  The purchased call option does not impact the calculation of diluted earnings per share as it is always anti-dilutive. The sold warrants become dilutive when our average stock price for a quarter exceeds the strike price of the warrant.

The following table provides examples of how changes in our stock price impact the number of shares that would be included in our diluted earnings per share calculation at June 30, 2013.  It also shows the impact on the number of shares issuable upon conversion of the Notes and settlement of the purchased call options and sold warrants:

   
Shares
     
Total Treasury
  
Shares Due
  
Incremental
 
   
Underlying 1.875%
     
Method
  
to the Company
  
Shares Issued/
 
Share
  
Convertible
  
Warrant
  
Incremental
  
under Notes
  
(Received) by the Company
 
Price
  
Notes
  
Shares
  
Shares (a)
  
Hedges
  
upon Conversion (b)
 
$80.73   56,988   -   56,988   (60,964)  (3,976)
$90.73   312,231   -   312,231   (334,015)  (21,784)
$100.73   516,795   -   516,795   (552,852)  (36,057)
$110.73   684,411   121,267   805,678   (732,163)  73,515 
$120.73   824,260   321,473   1,145,733   (881,769)  263,964 
$130.73   942,714   491,051   1,433,765   (1,008,487)  425,278 

a)  
Represents the number of incremental shares that must be included in the calculation of fully diluted shares under U.S. GAAP.
b)  
Represents the number of incremental shares to be issued by the Company upon conversion of the 1.875% Convertible Notes, assuming concurrent settlement of the note hedges and warrants.
 
 
- 8 -

 
 
5.     Long-Term Debt
 
On January 18, 2013, we replaced our existing credit agreement with our Revolving Credit Facility (“2013 Credit Agreement”).  Terms of the 2013 Credit Agreement consist of a five-year, $350 million revolving credit facility.  This 2013 Credit Agreement has a floating interest rate that is currently LIBOR plus 125 basis points.  The 2013 Credit Agreement also includes a $150 million expansion feature.  Debt issuance costs associated with the existing credit agreement were not material.  With respect to the 2013 Credit Agreement, deferred financing costs are immaterial.  The 2013 Credit Agreement contains the following quarterly financial covenants:
 
     
Description
 
Requirement
     
Leverage Ratio (Consolidated Indebtedness/Consolidated  Adj. EBITDA)
 
< 3.50 to 1.00
     
Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges)
 
> 1.50 to 1.00
     
Annual Operating Lease Commitment
 
< $30.0 million

We are in compliance with all debt covenants as of June 30, 2013.  We have issued $33.0 million in standby letters of credit as of June 30, 2013 for insurance purposes.  Issued letters of credit reduce our available credit under the 2013 Credit Agreement.  As of June 30, 2013, we have approximately $317.0 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility, excluding the $150 million expansion feature.

The following amounts are included in our consolidated balance sheet related to the Notes:
        
   
June 30, 2013
  
December 31, 2012
 
Principal amount of convertible debentures
 $186,956  $186,956 
Unamortized debt discount
  (7,802)  (12,066)
Carrying amount of convertible debentures
 $179,154  $174,890 
Additional paid in capital (net of tax)
 $31,310  $31,310 

In the second quarter of 2013, the principal amount of the convertible debentures was reclassified to current as the amounts are due in May 2014.

The following amounts comprise interest expense included in our consolidated income statement (in thousands):
             
  Three months ended June 30,  Six months ended June 30, 
 
2013
  
2012
  
2013
  
2012
 
Cash interest expense
$1,230  $1,350  $2,430  $2,683 
Non-cash amortization of debt discount
 2,150   2,009   4,264   3,985 
Amortization and write-off of debt costs
 317   313   1,097   621 
Total interest expense
$3,697  $3,672  $7,791  $7,289 

The unamortized debt discount is being amortized using the effective interest method over the remaining life of the Notes.  The effective rate on the Notes is approximately 6.875% as of June 30, 2013.

 
- 9 -

 

6.     Other Income/(expense) – Net

Other income/(expense) -- net comprises the following (in thousands):
              
   Three months ended June 30,  
Six months ended June 30,
 
   
2013
  
2012
  
2013
  
2012
 
Market value gains/(losses) on assets held in
            
deferred compensation trust
 $1,063  $(948) $2,535  $1,185 
Loss on disposal of property and equipment
  (1)  (67)  (79)  (148)
Interest income
  670   59   973   110 
Other - net
  (36)  (14)  (27)  (22)
     Total other income/(expense) - net
 $1,696  $(970) $3,402  $1,125 

 7.    Stock-Based Compensation Plans

On February 20, 2013, the Compensation/Incentive Committee of the Board of Directors (“CIC”) approved a grant of 28,992 shares of restricted stock to certain key employees.  The restricted shares cliff vest four years from the date of issuance.  The cumulative compensation expense related to the restricted stock award is $2.3 million and will be recognized ratably over the 4 year vesting period.  We assumed no forfeitures in determining the cumulative compensation expense of the grant.

8.     Independent Contractor Operations

The Roto-Rooter segment sublicenses with 66 independent contractors to operate certain plumbing repair and drain claning businesses in lesser-populated areas of the United States and Canada.  We had notes receivable from our independent contractors as of June 30, 2013 totaling $1.2 million (December 31, 2012 - $1.3 million).  In most cases these loans are fully or partially secured by equipment owned by the contractor.  The interest rates on the loans range from 0% to 8% per annum and the remaining terms of the loans range from 2 months to 5 years at June 30, 2013.  We recorded the following from our independent contractors (in thousands):
              
   Three months ended June 30,  Six months ended June 30, 
   
2013
  
2012
  
2013
  
2012
 
Revenues
 $8,154  $6,809  $16,364  $13,491 
Pretax profits
  4,513   3,732   8,771   6,813 

9.     Retirement Plans

All of the Company’s plans that provide retirement and similar benefits are defined contribution plans.  These expenses include the impact of market gains and losses on assets held in deferred compensation plans.  Expenses for the Company’s pension and profit-sharing plans, excess benefit plans and other similar plans are as follows (in thousands):

Three months ended June 30,
 
Six months ended June 30,
2013
 
2012
 
2013
 
2012
$3,402 $1,162 $7,698 $5,854

10.  Legal and Regulatory Matters

The VITAS segment of the Company’s business operates in a heavily-regulated industry.  As a result, the Company is subjected to inquiries and investigations by various government agencies, as well as to lawsuits, including qui tam actions.  The following sections describe the various ongoing lawsuits and investigations of which the Company is currently aware.  It is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or estimable.
 
 
- 10 -

 
 
Regulatory Matters and Litigation
In February 2010, Chemed and Roto-Rooter were named as defendants in a lawsuit filed in the United States District Court for the Eastern District of New York, entitled Anthony Morangelli, et al., v. Chemed Corp. and Roto-Rooter Services Co., No. 10 CV-00876 (BMC).  The named plaintiffs in this lawsuit, who are current and former technicians employed by Roto-Rooter who were paid on a commission basis, asserted against Chemed and Roto-Rooter claims for violation of the Fair Labor Standards Act (“FLSA”) and claims for violations of the labor laws of multiple states.  In June 2013 the parties reached an agreement to settle the case for $14.3 million plus applicable payroll taxes ($9.0 million after tax), which is subject to Court approval.  As such, $14.8 million is recorded as other operating expense in the quarter ended June 30, 2013 Statement of Income.
 
VITAS is party to a class action lawsuit filed in the Superior Court of California, Los Angeles County in September 2006 by Bernadette Santos, Keith Knoche and Joyce White, Bernadette Santos, et al. v. Vitas Healthcare Corporation of California, BC359356.  This case alleges failure to pay overtime and failure to provide meal and rest periods to a purported class of California admissions nurses, chaplains and sales representatives.  The case seeks payment of penalties, interest and Plaintiffs’ attorney fees.  We contest these allegations.  In December 2009, the trial court denied Plaintiffs’ motion for class certification.  In July 2011, the Court of Appeals affirmed denial of class certification on the travel time, meal and rest period claims, and reversed the trial court’s denial on the off-the-clock and sales representation exemption claims.  Plaintiffs filed an appeal of this decision.  In September 2012, in response to an order of reconsideration, the Court of Appeals reiterated its previous rulings.  In March 2013, the Court granted summary judgment dismissing the sales representatives’ claims as they are exempt employees.
 
On January 12, 2012, the Greater Pennsylvania Carpenters Pension Fund filed a putative class action lawsuit in the U.S. District Court for the Southern District of Ohio against the Company, Kevin McNamara, David Williams, and Timothy O’Toole.  On April 9, 2012, the Court issued orders (a) renaming the suit as In re Chemed Corp. Securities Litigation, Civil Action No. 1:12-cv-28 (S.D. Ohio); (b) appointing the Greater Pennsylvania Carpenters Pension Fund and the Electrical Workers Pension Fund, Local 103, I.B.E.W. as Lead Plaintiffs; and (c) approving Lead Plaintiffs’ selection of Labaton Sucharow LLP and Robbins Geller Rudman & Dowd LLP as Co-Lead Counsel.  On June 18, 2012, Lead Plaintiffs filed an amended complaint alleging violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 against all Defendants, and violation of Section 20(a) of the Securities Exchange Act of 1934 against Messrs. McNamara, Williams, and O’Toole.  The suit’s allegations concern the VITAS hospice segment of the Company’s business.  Lead Plaintiffs seek, on behalf of a putative class of purchasers of Chemed Capital Stock between February 15, 2010 and November 16, 2011, compensatory damages in an unspecified amount and attorneys’ fees and expenses, arising from Defendants’ failure to disclose an alleged fraudulent scheme to enroll ineligible hospice patients and to fraudulently obtain payments from the federal government.  Defendants filed motions to dismiss the amended complaint on August 17, 2012.  On June 7, 2013, following the filing of U.S. v. VITAS, discussed below, Plaintiffs filed a motion for leave to file a second amended complaint.  Defendants oppose this motion.   Defendants believe the Plaintiffs’ claims are without merit, and intend to defend vigorously against them.
 
In April 2005, VITAS received a subpoena from the Office of the Inspector General (“OIG”) of the U.S. Department of Health and Human Services requesting that VITAS produce various categories of documents from 1998 through the date of the subpoena in connection with an investigation into an alleged failure to appropriately bill Medicare and Medicaid for hospice services.  The requested categories of documents included patient medical and billing records for 320 past and then current patients from VITAS’s three largest programs; policy and procedure manuals; information concerning patient admissions, certifications, discharges, and lengths of stay; and census information.  In the third quarter of 2005, the OIG requested additional information from us.  In May 2006, VITAS received another subpoena from OIG seeking certain information concerning employees and their compensation from 1999 through 2004. In 2004, two former VITAS employees filed a related qui tam suit in U.S. District Court for the Southern District of Florida, United States, et al. ex rel. Barys v. Vitas Healthcare Corp., 1:04-cv-21431.  The complaint asserted violations of the federal False Claims Act against VITAS and certain of its affiliates, based on the alleged fraudulent admissions and recertification of ineligible patients.  In July 2007, the district court dismissed the suit with prejudice.  The U.S. Court of Appeals for the Eleventh Circuit affirmed the dismissal in November 2008.  In March 2009, VITAS received a letter from the Department of Justice indicating that its investigation of VITAS’s Florida programs is ongoing.
 
In July 2012, VITAS received an investigative subpoena from the Florida Attorney General seeking documents previously produced in the course of prior OIG government investigations as well as, for the period January 1, 2007 through the date of production, billing records and procedures; information concerning business results, plans, and strategies; documents concerning patient eligibility for hospice care; and certain information concerning employees and their compensation.
 
 
- 11 -

 
 
In May 2009, VITAS received an administrative subpoena from the U.S. Department of Justice requesting that VITAS deliver to the OIG various categories of documents for its headquarters and Texas programs from January 1, 2003 through the date of the subpoena.  The requested categories included policy and procedure manuals and information concerning Medicare and Medicaid billing and the provision of hospice services; patient medical records; information concerning business plans, strategies, and results and VITAS’s affiliated entities and referral sources; and certain information concerning employees and their compensation.  In August 2009, the OIG selected medical records for 59 past and current patients from a Texas program for review.  In September 2010, VITAS received a second administrative subpoena from the Department of Justice seeking electronic documents of 10 current and former employees.  In April 2011, the U.S. Attorney provided the Company with a copy of a qui tam complaint filed under seal in the U.S. District Court for the Northern District of Texas, United States, et al. ex rel. Rehfeldt v. Vitas Healthcare Corp., 3:09-cv-0203.  In November 2011, the complaint was unsealed.  The U.S. Attorney and the Attorney General for the State of Texas filed notices in November 2011 stating that they had decided not to intervene in the case at that time but indicating that they continue to investigate the allegations.  The complaint asserts violations of the federal False Claims Act and the Texas Medicaid Fraud Prevention Act based on the alleged admission and re-certification of ineligible patients, conspiracy to admit ineligible patients, and backdating patient revocations.  The suit was brought by Michael Rehfeldt, a former general manager of VITAS’s San Antonio program, against VITAS, the San Antonio program’s former Regional Vice-President, Keith Becker, and former Medical Director, Justo Cisneros, and their respective then-current employers: Wellmed Medical Management, Care Level Management, LLC, Inspiris Hospice, LLC, and Inspiris, Inc.  On May 1, 2013 following the plaintiff’s motion to dismiss voluntarily and the government’s consent, the Court dismissed this complaint without prejudice.
 
In February 2010, VITAS received a companion civil investigative demand (“CID”) from the Texas Attorney General seeking documents from January 1, 2002 through the date of the CID, and interrogatory responses in connection with a related investigation of possible fraudulent submission of Medicaid claims for non-qualifying patients and fraudulent shifting of costs from VITAS to the State of Texas and the United States.  The CID requested similar information sought by the Department of Justice’s May 2009 administrative subpoena, together with information concerning record-keeping and retention practices, and medical records concerning 117 patients.  In September 2010, VITAS received a second CID from the Texas Attorney General seeking additional documents concerning business plans and results, revocation forms for certain patients, and electronic documents of 10 current and former employees.
 
In June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Western District of Texas, United States, et al. ex rel. Urick v. Vitas HME Solutions, Inc. et al., 5:08-cv-0663 (“Urick”).  The U.S. Attorney filed a notice in May 2012 stating that it had decided not to intervene in the case at that time but indicating that it continues to investigate the allegations.  In June 2012, the complaint was unsealed.  The complaint asserts violations of the federal False Claims Act and the Texas Medicaid Fraud Prevention Act based on allegations of a conspiracy to submit to Medicare and Medicaid false claims involving hospice services for ineligible patients, unnecessary medical supplies, failing to satisfy certain prerequisites for payment, and altering patient records, including backdating patient revocations.  The suit was brought by Barbara Urick, a registered nurse in VITAS’s San Antonio program, against VITAS, certain of its affiliates, and several former VITAS employees, including physicians Justo Cisneros and Antonio Cavasos and nurses Sally Schwenk, Diane Anest, and Edith Reed.  In September 2012, the plaintiff dismissed all claims against the individual defendants.  The complaint was served on the VITAS entities on April 12, 2013.
 
Also in June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Northern District of Illinois, United States, et al. ex rel. Spottiswood v. Chemed Corp., 1:07-cv-4566 (“Spottiswood”).  In April 2012, the complaint was unsealed.  The U.S. Attorney and Attorney General for the State of Illinois filed notices in April and May 2012, respectively, stating that they had decided not to intervene in the case at that time but indicating that they continue to investigate the allegations.  Plaintiff filed an amended complaint in November 2012.  The complaint asserts violations of the federal False Claims Act and the Illinois Whistleblower Reward and Protection Act based on allegations that VITAS fraudulently billed Medicare and Medicaid for providing unwarranted continuous care services.  The suit was brought by Laura Spottiswood, a former part-time pool registered nurse at VITAS, against Chemed, VITAS, and a VITAS affiliate.  The complaint was served on the defendants on    April 12, 2013.  On May 29 and June 4, 2013, respectively, the Court granted the government’s motion to partially intervene in Spottiswood and in Urick on the allegations that Vitas submitted or caused to be submitted false or fraudulent claims for continuous care and routine home care on behalf of certain ineligible Medicare beneficiaries.  The Court also transferred them to the U.S. District Court for the Western District of Missouri under docket Nos. 4:13-cv-505 and 4:13-cv-563, respectively.  The government has told Vitas it intends to consolidate these cases with the 2013 Action described below.
 
In June 2012, VITAS received an administrative subpoena from OIG in connection with an investigation of possible improper claims submitted to the Medicare and Medicaid programs.  It seeks production of various categories of documents concerning the provision of hospice services, for headquarters and its Southern California programs, for the period January 1, 2007 through the date of the subpoena.  The categories of documents include policy, procedure and training manuals; documents concerning patient eligibility for hospice care, including referrals, admissions, certifications, revocations and census information; documents concerning claims submitted to government programs; certain information concerning employees and their compensation; and documents concerning VITAS’s financial performance.  In August 2012, the OIG also subpoenaed medical records for 268 patients from three Southern California programs.
 
 
- 12 -

 
 
In September 2012, VITAS received an administrative subpoena from OIG seeking production of medical records for 102 patients in 10 states who received continuous care between 2004 and 2009.  In December 2012, it received a second such administrative subpoena from the OIG seeking medical records for 103 patients who received continuous care between 2009 and 2012.
 
On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiaries in the U.S. District Court for the Western District of Missouri, United States v. VITAS Hospice Services, LLC, et al., 4:13-cv-00449-BCW (the “2013 Action”).  The 2013 Action alleges that, since at least 2002, VITAS, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for continuous home care services when the patients were not eligible, the services were not provided, or the medical care was inappropriate, and (b) billing Medicare for patients who were not eligible for the Medicare hospice benefit because they did not have a life expectancy of six months or less if their illnesses ran their normal course.  This complaint seeks treble damages, statutory penalties, and the costs of the action, plus interest.  
 
On May 6, 2013, the U.S. District Court for the Western District of Missouri, at the request of the government, unsealed a qui tam complaint against VITAS and VITAS Healthcare Corporation of California, United States ex rel. Charles Gonzales v. Vitas Healthcare Corporation, et al., CV 12-0761-R (“Gonzales”).  The case was transferred from the Central District of California to the Western District of Missouri under docket No. 4:13-cv-344.  The government has filed a notice of election to intervene in the Gonzales complaint.  The Gonzales complaint alleges that VITAS’ Los Angeles program falsely certified and recertified patients as eligible for the Medicare Hospice Benefit.  It alleges violations of the False Claims Act and seeks treble damages, civil penalties, recovery of costs, attorneys’ fees and expenses, and pre- and post-judgment interest.   In its notice of election to intervene in Gonzales, the government stated that it intends to seek to consolidate the 2013 Action with Gonzales as a related matter. Upon consolidation, the government stated that the complaint in the 2013 Action will supersede the Gonzales complaint.
 
The Company intends to defend vigorously against the allegations in each of the above lawsuits.  The costs to comply with these investigations were $996,000 and $2.0 million for the three and six month periods ended June 30, 2013.  Regardless of the outcome of any of the preceding matters, responding to the subpoenas and dealing with the various regulatory agencies can adversely affect us through defense costs, diversion of management time, and related publicity.

11.   Concentration of Risk
 
VITAS has pharmacy services agreements ("Agreements") with Omnicare, Inc. and its subsidiaries (“OCR”) whereby OCR provides specified pharmacy services for VITAS and its hospice patients in geographical areas served by both VITAS and OCR.  The Agreements renew automatically for one-year terms.  Either party may cancel the Agreements at the end of any term by giving 90 days prior written notice.  VITAS made purchases from OCR of $9.9 million and $10.2 million for the three months ended June 30, 2013 and 2012, respectively.  VITAS made purchases from OCR of $19.5 million and $20.3 million for the six months ended June 30, 2013 and 2012, respectively For the three and six month periods ending June 30, 2013 and 2012, respectively, purchases from this vendor represent over 90% of all pharmacy services used by VITAS.

12.   Cash Overdrafts and Cash Equivalents

Included in accounts payable at June 30, 2013 is cash overdrafts payable of $613,000 (December 31, 2012 - $12.2 million).

From time to time throughout the year, we invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds.  We had $77.6 million in cash equivalents as of June 30, 2013.  There was $56.6 million in cash equivalents as of December 31, 2012.  The weighted average rate of return for our cash equivalents was 0.09% for June 30, 2013 and 0.2% for December 31, 2012.

 
- 13 -

 

13.   Financial Instruments

FASB’s authoritative guidance on fair value measurements defines a hierarchy which prioritizes the inputs in fair value measurements.  Level 1 measurements are measurements using quoted prices in active markets for identical assets or liabilities.  Level 2 measurements use significant other observable inputs.  Level 3 measurements are measurements using significant unobservable inputs which require a company to develop its own assumptions.  In recording the fair value of assets and liabilities, companies must use the most reliable measurement available.

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of June 30, 2013 (in thousands):
              
      
Fair Value Measure
 
   
Carrying Value
  
Quoted Prices in
 Active Markets for
 Identical Assets
 (Level 1)
  
Significant Other
 Observable Inputs
 (Level 2)
  
Significant
Unobservable
Inputs (Level 3)
 
Mutual fund investments of deferred
            
compensation plans held in trust
 $40,583  $40,583  $-  $- 
Long-term debt
  179,154   199,041   -   - 

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of      December 31, 2012 (in thousands):

              
      
Fair Value Measure
 
   
Carrying Value
  
Quoted Prices in
 Active Markets for
 Identical Assets
 (Level 1)
  
Significant Other
 Observable Inputs
 (Level 2)
  
Significant
Unobservable
Inputs (Level 3)
 
Mutual fund investments of deferred
            
compensation plans held in trust
 $36,089  $36,089  $-  $- 
Long-term debt
  174,890   197,874   -   - 

For cash and cash equivalents, accounts receivable and accounts payable, the carrying amount is a reasonable estimate of fair value because of the liquidity and short-term nature of these instruments.

14.   Capital Stock Repurchase Plan Transactions

We repurchased the following capital stock for the three and six-months ended June 30, 2013 and 2012:
              
   Three months ended June 30,  
Six months ended June 30,
 
   
2013
  
2012
  
2013
  
2012
 
              
Shares repurchased
  280,701   199,900   280,701   199,900 
Weighted average price per share
 $65.72  $55.72  $65.72  $55.72 

In February 2013, the Board of Directors authorized an additional $100 million for stock repurchase under Chemed’s existing share repurchase program. We currently have $96.3 million of authorization remaining under this share repurchase plan.
 
 
- 14 -

 
 
15.   Guarantor Subsidiaries
Our 1.875% Notes are fully and unconditionally guaranteed on an unsecured, jointly, and severally liable basis by certain of our 100% owned subsidiaries.  The following unaudited, condensed, consolidating financial data presents the composition of the parent company (Chemed), the guarantor subsidiaries and the non-guarantor subsidiaries as of June 30, 2013 and December 31, 2012 for the balance sheet, the three and six months ended June 30, 2013 and June 30, 2012 for the income statement and the six months ended June 30, 2013 and June 30, 2012 for the statement of cash flows  (dollars in thousands):
                 
June 30, 2013
    
Guarantor
  
Non-Guarantor
  
Consolidating
    
 
 
Parent
  
Subsidiaries
  
Subsidiaries
  
Adjustments
  
Consolidated
 
ASSETS
               
Cash and cash equivalents
 $113,927  $(9,574) $8,694  $-  $113,047 
Accounts receivable, including intercompany
  1,005   466,915   1,076   (392,640)  76,356 
Inventories
  -   5,553   603   -   6,156 
Current deferred income taxes
  -   21,462   267   (2,407)  19,322 
Prepaid income taxes
  6,494   327   -   (1,910)  4,911 
Prepaid expenses
  1,652   11,676   190   -   13,518 
     Total current assets
  123,078   496,359   10,830   (396,957)  233,310 
Investments of deferred compensation plans
  -   -   40,583   -   40,583 
Properties and equipment, at cost less accumulated depreciation
  10,584   76,963   2,682   -   90,229 
Identifiable intangible assets less accumulated amortization
  -   57,348   -   -   57,348 
Goodwill
  -   461,801   4,470   -   466,271 
Other assets
  18,049   1,757   14,930   (23,599)  11,137 
Investments in subsidiaries
  908,756   25,726   -   (934,482)  - 
          Total assets
 $1,060,467  $1,119,954  $73,495  $(1,355,038) $898,878 
LIABILITIES AND STOCKHOLDERS' EQUITY
                    
Accounts payable, including intercompany
 $385,095  $37,026  $6,440  $(392,640) $35,921 
Current portion of long-term debt
  179,154   -   -   -   179,154 
Income taxes
  3,776   1,205   1,490   (1,910)  4,561 
Accrued insurance
  1,581   41,035   -   -   42,616 
Accrued compensation
  2,128   39,631   397   -   42,156 
Other current liabilities
  4,297   31,596   354   (2,407)  33,840 
      Total current liabilities
  576,031   150,493   8,681   (396,957)  338,248 
Deferred income taxes
  -   51,580   -   (23,599)  27,981 
Long-term debt
  -   -   -   -   - 
Deferred compensation liabilities
  -   -   39,660   -   39,660 
Other liabilities
  3,149   7,639   914   -   11,702 
Stockholders' equity
  481,287   910,242   24,240   (934,482)  481,287 
     Total liabilities and stockholders' equity
 $1,060,467  $1,119,954  $73,495  $(1,355,038) $898,878 
                      
December 31, 2012
     
Guarantor
  
Non-Guarantor
  
Consolidating
     
 
 
Parent
  
Subsidiaries
  
Subsidiaries
  
Adjustments
  
Consolidated
 
ASSETS
                    
Cash and cash equivalents
 $56,342  $4,674  $8,515  $-  $69,531 
Accounts receivable, including intercompany
  925   427,341   889   (335,822)  93,333 
Inventories
  -   6,505   553   -   7,058 
Current deferred income taxes
  -   14,633   173   (1,147)  13,659 
Prepaid income taxes
  4,043   -   -   (1,400)  2,643 
Prepaid expenses
  564   10,656   227   -   11,447 
     Total current assets
  61,874   463,809   10,357   (338,369)  197,671 
Investments of deferred compensation plans
  -   -   36,089   -   36,089 
Properties and equipment, at cost less accumulated depreciation
  10,984   78,236   2,714   -   91,934 
Identifiable intangible assets less accumulated amortization
  -   57,177   -   -   57,177 
Goodwill
  -   461,277   4,555   -   465,832 
Other assets
  19,025   2,005   13,797   (23,904)  10,923 
Investments in subsidiaries
  874,692   24,298   -   (898,990)  - 
          Total assets
 $966,575  $1,086,802  $67,512  $(1,261,263) $859,626 
LIABILITIES AND STOCKHOLDERS' EQUITY
                    
Accounts payable, including intercompany
 $325,916  $53,934  $4,444  $(335,822) $48,472 
Income taxes
  1,019   3,816   1,503   (1,400)  4,938 
Accrued insurance
  1,339   39,315   -   -   40,654 
Accrued compensation
  4,119   40,891   447   -   45,457 
Other current liabilities
  2,786   13,903   1,759   (1,147)  17,301 
      Total current liabilities
  335,179   151,859   8,153   (338,369)  156,822 
Deferred income taxes
  -   51,566   -   (23,904)  27,662 
Long-term debt
  174,890   -   -   -   174,890 
Deferred compensation liabilities
  -   -   35,599   -   35,599 
Other liabilities
  3,215   7,352   795   -   11,362 
Stockholders' equity
  453,291   876,025   22,965   (898,990)  453,291 
     Total liabilities and stockholders' equity
 $966,575  $1,086,802  $67,512  $(1,261,263) $859,626 
 
 
- 15 -

 

For the three months ended June 30, 2013
    
Guarantor
  
Non-Guarantor
  
Consolidating
    
 
 
Parent
  
Subsidiaries
  
Subsidiaries
  
Adjustments
  
Consolidated
 
Continuing Operations
               
Service revenues and sales
 $-  $349,643  $7,555  $-  $357,198 
Cost of services provided and goods sold
  -   251,131   4,228   -   255,359 
Selling, general and administrative expenses
  5,856   44,734   2,517   -   53,107 
Depreciation
  238   6,419   242   -   6,899 
Amortization
  497   684   -   -   1,181 
Other operating expenses
  -   14,760   -   -   14,760 
     Total costs and expenses
  6,591   317,728   6,987   -   331,306 
     Income/ (loss) from operations
  (6,591)  31,915   568   -   25,892 
Interest expense
  (3,535)  (148)  (14)  -   (3,697)
Other (expense)/income - net
  4,309   (3,674)  1,061   -   1,696 
     Income/ (loss) before income taxes
  (5,817)  28,093   1,615   -   23,891 
Income tax (provision)/ benefit
  1,861   (10,545)  (599)  -   (9,283)
Equity in net income of subsidiaries
  18,564   1,061   -   (19,625)  - 
Net income
 $14,608  $18,609  $1,016  $(19,625) $14,608 
                      
For the three months ended June 30, 2012
     
Guarantor
  
Non-Guarantor
  
Consolidating
     
 
 
Parent
  
Subsidiaries
  
Subsidiaries
  
Adjustments
  
Consolidated
 
Continuing Operations
                    
Service revenues and sales
 $-  $347,017  $7,153  $-  $354,170 
Cost of services provided and goods sold
  -   253,434   3,934   -   257,368 
Selling, general and administrative expenses
  5,937   43,356   477   -   49,770 
Depreciation
  234   5,926   220   -   6,380 
Amortization
  481   646   -   -   1,127 
     Total costs and expenses
  6,652   303,362   4,631   -   314,645 
     Income/ (loss) from operations
  (6,652)  43,655   2,522   -   39,525 
Interest expense
  (3,487)  (171)  (14)  -   (3,672)
Other (expense)/income - net
  4,340   (4,357)  (953)  -   (970)
     Income/ (loss) before income taxes
  (5,799)  39,127   1,555   -   34,883 
Income tax (provision)/ benefit
  1,918   (14,918)  (609)  -   (13,609)
Equity in net income of subsidiaries
  25,155   990   -   (26,145)  - 
Net income
 $21,274  $25,199  $946  $(26,145) $21,274 
                      
For the six months ended June 30, 2013
     
Guarantor
  
Non-Guarantor
  
Consolidating
     
 
 
Parent
  
Subsidiaries
  
Subsidiaries
  
Adjustments
  
Consolidated
 
Continuing Operations
                    
Service revenues and sales
 $-  $708,699  $15,140  $-  $723,839 
Cost of services provided and goods sold
  -   511,108   8,558   -   519,666 
Selling, general and administrative expenses
  11,728   91,306   5,633   -   108,667 
Depreciation
  478   12,744   472   -   13,694 
Amortization
  979   1,329   -   -   2,308 
Other operating expenses
  -   14,760   -   -   14,760 
     Total costs and expenses
  13,185   631,247   14,663   -   659,095 
     Income/ (loss) from operations
  (13,185)  77,452   477   -   64,744 
Interest expense
  (7,510)  (253)  (28)  -   (7,791)
Other (expense)/income - net
  8,582   (7,709)  2,529   -   3,402 
     Income/ (loss) before income taxes
  (12,113)  69,490   2,978   -   60,355 
Income tax (provision)/ benefit
  3,994   (26,362)  (1,101)  -   (23,469)
Equity in net income of subsidiaries
  45,005   1,971   -   (46,976)  - 
Net income
 $36,886  $45,099  $1,877  $(46,976) $36,886 
                      
For the six months ended June 30, 2012
     
Guarantor
  
Non-Guarantor
  
Consolidating
     
 
 
Parent
  
Subsidiaries
  
Subsidiaries
  
Adjustments
  
Consolidated
 
Continuing Operations
                    
Service revenues and sales
 $-  $692,631  $14,482  $-  $707,113 
Cost of services provided and goods sold
  -   506,861   7,952   -   514,813 
Selling, general and administrative expenses
  11,133   87,703   4,101   -   102,937 
Depreciation
  467   11,717   437   -   12,621 
Amortization
  951   1,289   -   -   2,240 
     Total costs and expenses
  12,551   607,570   12,490   -   632,611 
     Income/ (loss) from operations
  (12,551)  85,061   1,992   -   74,502 
Interest expense
  (6,920)  (340)  (29)  -   (7,289)
Other (expense)/income - net
  8,746   (8,798)  1,177   -   1,125 
     Income/ (loss) before income taxes
  (10,725)  75,923   3,140   -   68,338 
Income tax (provision)/ benefit
  3,499   (28,882)  (1,236)  -   (26,619)
Equity in net income of subsidiaries
  48,945   1,972   -   (50,917)  - 
Net income
 $41,719  $49,013  $1,904  $(50,917) $41,719 
 
 
- 16 -

 

For the six months ended June 30, 2013
    
Guarantor
  
Non-Guarantor
    
   
Parent
  
Subsidiaries
  
Subsidiaries
  
Consolidated
 
Cash Flow from Operating Activities:
            
Net cash provided/(used) by operating activities
 $3,623  $81,919  $(876) $84,666 
Cash Flow from Investing Activities:
                
 Capital expenditures
  (79)  (11,664)  (457)  (12,200)
 Business combinations, net of cash acquired
  -   (1,501)  -   (1,501)
 Other sources/(uses) - net
  (31)  114   18   101 
      Net cash used by investing activities
  (110)  (13,051)  (439)  (13,600)
Cash Flow from Financing Activities:
                
 Increase /(decrease) in cash overdrafts payable
  4,361   (15,969)  -   (11,608)
 Change in intercompany accounts
  65,257   (67,147)  1,890   - 
 Dividends paid
  (6,775)  -   -   (6,775)
 Debt issuance costs
  (1,104)  -   -   (1,104)
 Capital stock surrendered to pay taxes on stock-based compensation
  (4,269)  -   -   (4,269)
 Purchases of treasury stock
  (18,448)  -   -   (18,448)
 Proceeds from exercise of stock options
  12,558   -   -   12,558 
 Excess tax benefit on share-based compensation
  2,478   -   -   2,478 
 Other sources/(uses) - net
  14   -   (396)  (382)
      Net cash provided/(used) by financing activities
  54,072   (83,116)  1,494   (27,550)
Net increase in cash and cash equivalents
  57,585   (14,248)  179   43,516 
Cash and cash equivalents at beginning of year
  56,342   4,674   8,515   69,531 
Cash and cash equivalents at end of period
 $113,927  $(9,574) $8,694  $113,047 
                  
For the six months ended June 30, 2012
     
Guarantor
  
Non-Guarantor
     
   
Parent
  
Subsidiaries
  
Subsidiaries
  
Consolidated
 
Cash Flow from Operating Activities:
                
Net cash provided/(used) by operating activities
 $(3,716) $57,667  $704  $54,655 
Cash Flow from Investing Activities:
                
 Capital expenditures
  (28)  (17,966)  (480)  (18,474)
 Business combinations, net of cash acquired
  -   (1,500)  -   (1,500)
 Other sources/(uses) - net
  200   167   (10)  357 
      Net cash provided/(used) by investing activities
  172   (19,299)  (490)  (19,617)
Cash Flow from Financing Activities:
                
 Increase/(decrease) in cash overdrafts payable
  (46)  1,031   -   985 
 Change in intercompany accounts
  38,573   (38,780)  207   - 
 Dividends paid
  (6,160)  -   -   (6,160)
 Capital stock surrendered to pay taxes on stock-based compensation
  (1,645)  -   -   (1,645)
 Purchases of treasury stock
  (11,138)  -   -   (11,138)
 Proceeds from exercise of stock options
  3,670   -   -   3,670 
 Excess tax benefit on share-based compensation
  1,069   -   -   1,069 
 Other sources/(uses) - net
  31   -   35   66 
      Net cash provided/(used) by financing activities
  24,354   (37,749)  242   (13,153)
Net increase in cash and cash equivalents
  20,810   619   456   21,885 
Cash and cash equivalents at beginning of year
  32,470   (1,422)  7,033   38,081 
Cash and cash equivalents at end of period
 $53,280  $(803) $7,489  $59,966 
 
 
- 17 -

 

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

Executive Summary
We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc.  VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible.  Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families.  Roto-Rooter’s services are focused on providing plumbing and drain cleaning services to both residential and commercial customers.  Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The following is a summary of the key operating results (in thousands except per share amounts):
              
 
 
Three months ended June 30,
  
Six months ended June 30,
 
   
2013
  
2012
  
2013
  
2012
 
Service revenues and sales
 $357,198  $354,170  $723,839  $707,113 
Net income
 $14,608  $21,274  $36,886  $41,719 
Diluted EPS
 $0.77  $1.10  $1.94  $2.16 
Adjusted net income
 $27,232  $24,330  $53,372  $47,670 
Adjusted diluted EPS
 $1.44  $1.26  $2.81  $2.46 
Adjusted EBITDA
 $52,943  $48,173  $104,239  $94,513 
Adjusted EBITDA as a % of revenue
  14.8 %  13.6 %  14.4 %  13.4 %

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”) and Adjusted EBITDA are not measures derived in accordance with GAAP.  We use Adjusted EBITDA as a measure of earnings for our long-term incentive plan awards.  We provide non-GAAP measures to help readers evaluate our operating results, compare our operating performance with that of similar companies that have different capital structures and help evaluate our ability to meet future debt service, capital expenditure and working capital requirements.  Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP.  A reconciliation of our non-GAAP measures  are  presented on pages 31- 33.
 
For the three months ended June 30, 2013, the increase in consolidated service revenues and sales was driven by a 5.3% increase at Roto-Rooter and a 0.6% decrease at VITAS.  The increase in service revenues at Roto-Rooter was driven by a 2.4% increase in job count as well as a 2.9% increase in price and mix shift. The decrease in service revenues at VITAS was a result of Medicare reimbursement rates declining approximately 1.1%, increased ADC of 4.0%, an $855,000 Medicare cap charge during the quarter and level of care mix shift.  Consolidated net income decreased 31.3% primarily as a result of a tentative litigation settlement at Roto-Rooter.  Diluted EPS decreased 30.0% as a result of the decrease in net income offset by a lower number of shares outstanding.  Adjusted EBITDA as a percent of revenue increased 1.2% mainly as a result of improved gross profit margins at Roto-Rooter.  See page 34 for additional VITAS operating metrics.
 
For the six months ended June 30, 2013, the increase in consolidated service revenues and sales was driven by a 4.4% increase at Roto-Rooter and a 1.7% increase at VITAS.  The increase in service revenues at Roto-Rooter was driven by a 1.8% increase in job count as well as a 2.6% increase in price and mix shift. The increase in service revenues at VITAS was a result of a decrease in Medicare reimbursement rates, increased ADC of 4.7%, a $2.6 million net reversal of Medicare cap in 2012 that did not recur in 2013 and level of care mix shift.  Consolidated net income decreased 11.6% primarily as a result of a tentative litigation settlement at Roto-Rooter.  Diluted EPS decreased 10.2% as a result of the decrease in net income offset by a lower number of shares outstanding.  Adjusted EBITDA as a percent of revenue increased 1.0% mainly as a result of improved gross profit margins at Roto-Rooter.  See page 34 for additional VITAS operating metrics.
 
Effective October 1, 2012, Medicare increased the hospice reimbursement rates by approximately 0.9% and effective April 1, 2013, as a result of sequestration, Medicare reduced hospice reimbursement rates for Medicare beneficiaries 2.0% for a net decline of 1.1% in reimbursement rates.  The effect of changes in Medicare reimbursement rates impacts approximately 91.2% of VITAS’ revenue base.  VITAS expects to achieve full-year 2013 revenue growth, prior to Medicare cap, of 0.5% to 2.0%.  Admissions are estimated to increase approximately 2.0% to 4.0%.  Adjusted EBITDA margin, prior to Medicare cap, is estimated to be 14.0% to 14.5%.  Roto-Rooter expects full-year 2013 revenue of 4.0% to 5.0%.  The revenue estimate is a result of increased pricing of approximately 3.5%, a favorable mix shift to higher revenue jobs, with job count estimated to increase 0.5% to 1.0%.  Adjusted EBITDA margin for 2013 is estimated to be in the range of 19.0% to 19.5%.  We anticipate that our operating income and cash flows will be sufficient to operate our businesses and meet any commitments for the foreseeable future.
 
 
- 18 -

 
 
Financial Condition
Liquidity and Capital Resources
Material changes in the balance sheet accounts from December 31, 2012 to June 30, 2013 include the following:

  
A $17.0 million decrease in accounts receivable related to the timing of receipts.
  
A $12.6 million decrease in accounts payable due to timing of payments.
  
A $16.5 million increase in other current liabilities primarily due to a litigation settlement at Roto-Rooter.
  
A $179.2 million reclass of our convertible notes from long-term to current as they are due in May 2014.

Net cash provided by operating activities increased $30.0 million primarily as a result of a decrease in accounts receivable and an increase in other current liabilities.  Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.
 
We have issued $33.0 million in standby letters of credit as of June 30, 2013, for insurance purposes.  Issued letters of credit reduce our available credit under the revolving credit agreement.  As of June 30, 2013, we have approximately $317.0 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility, excluding the $150 million expansion feature. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

Commitments and Contingencies
Collectively, the terms of our credit agreements require us to meet various financial covenants, to be tested quarterly.  We are in compliance with all financial and other debt covenants as of June 30, 2013 and anticipate remaining in compliance throughout 2013.

The VITAS segment of the Company’s business operates in a heavily-regulated industry.  As a result, the Company is subjected to inquiries and investigations by various government agencies, as well as to lawsuits, including qui tam actions.  The following sections describe the various ongoing lawsuits and investigations of which the Company is currently aware.  It is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or estimable.

In February 2010, Chemed and Roto-Rooter were named as defendants in a lawsuit filed in the United States District Court for the Eastern District of New York, entitled Anthony Morangelli, et al., v. Chemed Corp. and Roto-Rooter Services Co., No. 10 CV-00876 (BMC).  The named plaintiffs in this lawsuit, who are current and former technicians employed by Roto-Rooter who were paid on a commission basis, asserted against Chemed and Roto-Rooter claims for violation of the Fair Labor Standards Act (“FLSA”) and claims for violations of the labor laws of multiple states.  In June 2013 the parties reached an agreement to settle the case for $14.3 million plus applicable payroll taxes ($9.0 million total after tax), which is subject to Court approval.  As such, $14.8 million is recorded as other operating expense in the quarter ended June 30, 2013 Statement of Income.
 
VITAS is party to a class action lawsuit filed in the Superior Court of California, Los Angeles County in September 2006 by Bernadette Santos, Keith Knoche and Joyce White, Bernadette Santos, et al. v. Vitas Healthcare Corporation of California, BC359356.  This case alleges failure to pay overtime and failure to provide meal and rest periods to a purported class of California admissions nurses, chaplains and sales representatives.  The case seeks payment of penalties, interest and Plaintiffs’ attorney fees.  We contest these allegations.  In December 2009, the trial court denied Plaintiffs’ motion for class certification.  In July 2011, the Court of Appeals affirmed denial of class certification on the travel time, meal and rest period claims, and reversed the trial court’s denial on the off-the-clock and sales representation exemption claims.  Plaintiffs filed an appeal of this decision.  In September 2012, in response to an order of reconsideration, the Court of Appeals reiterated its previous rulings.  In March 2013, the Court granted summary judgment dismissing the sales representatives’ claims as they are exempt employees.

On January 12, 2012, the Greater Pennsylvania Carpenters Pension Fund filed a putative class action lawsuit in the U.S. District Court for the Southern District of Ohio against the Company, Kevin McNamara, David Williams, and Timothy O’Toole.  On April 9, 2012, the Court issued orders (a) renaming the suit as In re Chemed Corp. Securities Litigation, Civil Action No. 1:12-cv-28 (S.D. Ohio); (b) appointing the Greater Pennsylvania Carpenters Pension Fund and the Electrical Workers Pension Fund, Local 103, I.B.E.W. as Lead Plaintiffs; and (c) approving Lead Plaintiffs’ selection of Labaton Sucharow LLP and Robbins Geller Rudman & Dowd LLP as Co-Lead Counsel.  On June 18, 2012, Lead Plaintiffs filed an amended complaint alleging violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 against all Defendants, and violation of Section 20(a) of the Securities Exchange Act of 1934 against Messrs. McNamara, Williams, and O’Toole.  The suit’s allegations concern the VITAS hospice segment of the Company’s business.  Lead Plaintiffs seek, on behalf of a putative class of purchasers of Chemed Capital Stock between February 15, 2010 and November 16, 2011, compensatory damages in an unspecified amount and attorneys’ fees and expenses, arising from Defendants’ failure to disclose an alleged fraudulent scheme to enroll ineligible hospice patients and to fraudulently obtain payments from the federal government.  Defendants filed motions to dismiss the amended complaint on August 17, 2012.  On June 7, 2013, following the filing of U.S. v. VITAS, discussed below, Plaintiffs’ filed a motion for leave to file a second amended complaint.  Defendants oppose this motion.   Defendants believe the Plaintiffs claims are without merit, and intend to defend vigorously against them.
 
 
- 19 -

 
 
In April 2005, VITAS received a subpoena from the Office of the Inspector General (“OIG”) of the U.S. Department of Health and Human Services requesting that VITAS produce various categories of documents from 1998 through the date of the subpoena in connection with an investigation into an alleged failure to appropriately bill Medicare and Medicaid for hospice services.  The requested categories of documents included patient medical and billing records for 320 past and then current patients from VITAS’s three largest programs; policy and procedure manuals; information concerning patient admissions, certifications, discharges, and lengths of stay; and census information.  In the third quarter of 2005, the OIG requested additional information from us.  In May 2006, VITAS received another subpoena from OIG seeking certain information concerning employees and their compensation from 1999 through 2004. In 2004, two former VITAS employees filed a related qui tam suit in U.S. District Court for the Southern District of Florida, United States, et al. ex rel. Barys v. Vitas Healthcare Corp., 1:04-cv-21431.  The complaint asserted violations of the federal False Claims Act against VITAS and certain of its affiliates, based on the alleged fraudulent admissions and recertification of ineligible patients.  In July 2007, the district court dismissed the suit with prejudice.  The U.S. Court of Appeals for the Eleventh Circuit affirmed the dismissal in November 2008.  In March 2009, VITAS received a letter from the Department of Justice indicating that its investigation of VITAS’s Florida programs is ongoing.

In July 2012, VITAS received an investigative subpoena from the Florida Attorney General seeking documents previously produced in the course of prior OIG government investigations as well as, for the period January 1, 2007 through the date of production, billing records and procedures; information concerning business results, plans, and strategies; documents concerning patient eligibility for hospice care; and certain information concerning employees and their compensation.
 
In May 2009, VITAS received an administrative subpoena from the U.S. Department of Justice requesting that VITAS deliver to the OIG various categories of documents for its headquarters and Texas programs from January 1, 2003 through the date of the subpoena.  The requested categories included policy and procedure manuals and information concerning Medicare and Medicaid billing and the provision of hospice services; patient medical records; information concerning business plans, strategies, and results and VITAS’s affiliated entities and referral sources; and certain information concerning employees and their compensation.  In August 2009, the OIG selected medical records for 59 past and current patients from a Texas program for review.  In September 2010, VITAS received a second administrative subpoena from the Department of Justice seeking electronic documents of 10 current and former employees.  In April 2011, the U.S. Attorney provided the Company with a copy of a qui tam complaint filed under seal in the U.S. District Court for the Northern District of Texas, United States, et al. ex rel. Rehfeldt v. Vitas Healthcare Corp., 3:09-cv-0203.  In November 2011, the complaint was unsealed.  The U.S. Attorney and the Attorney General for the State of Texas filed notices in November 2011 stating that they had decided not to intervene in the case at that time but indicating that they continue to investigate the allegations.  The complaint asserts violations of the federal False Claims Act and the Texas Medicaid Fraud Prevention Act based on the alleged admission and re-certification of ineligible patients, conspiracy to admit ineligible patients, and backdating patient revocations.  The suit was brought by Michael Rehfeldt, a former general manager of VITAS’s San Antonio program, against VITAS, the San Antonio program’s former Regional Vice-President, Keith Becker, and former Medical Director, Justo Cisneros, and their respective then-current employers: Wellmed Medical Management, Care Level Management, LLC, Inspiris Hospice, LLC, and Inspiris, Inc.  On May 1, 2013 following the plaintiff’s motion to dismiss voluntarily and the government’s consent, the Court dismissed this complaint without prejudice.
 
In February 2010, VITAS received a companion civil investigative demand (“CID”) from the Texas Attorney General seeking documents from January 1, 2002 through the date of the CID, and interrogatory responses in connection with a related investigation of possible fraudulent submission of Medicaid claims for non-qualifying patients and fraudulent shifting of costs from VITAS to the State of Texas and the United States.  The CID requested similar information sought by the Department of Justice’s May 2009 administrative subpoena, together with information concerning record-keeping and retention practices, and medical records concerning 117 patients.  In September 2010, VITAS received a second CID from the Texas Attorney General seeking additional documents concerning business plans and results, revocation forms for certain patients, and electronic documents of 10 current and former employees.
 
 
- 20 -

 
 
In June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Western District of Texas, United States, et al. ex rel. Urick v. Vitas HME Solutions, Inc. et al., 5:08-cv-0663 (“Urick”).  The U.S. Attorney filed a notice in May 2012 stating that it had decided not to intervene in the case at that time but indicating that it continues to investigate the allegations.  In June 2012, the complaint was unsealed.  The complaint asserts violations of the federal False Claims Act and the Texas Medicaid Fraud Prevention Act based on allegations of a conspiracy to submit to Medicare and Medicaid false claims involving hospice services for ineligible patients, unnecessary medical supplies, failing to satisfy certain prerequisites for payment, and altering patient records, including backdating patient revocations.  The suit was brought by Barbara Urick, a registered nurse in VITAS’s San Antonio program, against VITAS, certain of its affiliates, and several former VITAS employees, including physicians Justo Cisneros and Antonio Cavasos and nurses Sally Schwenk, Diane Anest, and Edith Reed.  In September 2012, the plaintiff dismissed all claims against the individual defendants.  The complaint was served on the VITAS entities on April 12, 2013.

Also in June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Northern District of Illinois, United States, et al. ex rel. Spottiswood v. Chemed Corp., 1:07-cv-4566 (“Spottiswood”).  In April 2012, the complaint was unsealed.  The U.S. Attorney and Attorney General for the State of Illinois filed notices in April and May 2012, respectively, stating that they had decided not to intervene in the case at that time but indicating that they continue to investigate the allegations.  Plaintiff filed an amended complaint in November 2012.  The complaint asserts violations of the federal False Claims Act and the Illinois Whistleblower Reward and Protection Act based on allegations that VITAS fraudulently billed Medicare and Medicaid for providing unwarranted continuous care services.  The suit was brought by Laura Spottiswood, a former part-time pool registered nurse at VITAS, against Chemed, VITAS, and a VITAS affiliate.  The complaint was served on the defendants on    April 12, 2013.  On May 29 and June 4, 2013, respectively, the Court granted the government’s motion to partially intervene in Spottiswood and in Urick on the allegations that Vitas submitted or caused to be submitted false or fraudulent claims for continuous care and routine home care on behalf of certain ineligible Medicare beneficiaries.  The Court also transferred them to the U.S. District Court for the Western District of Missouri under docket Nos. 4:13-cv-505 and 4:13-cv-563, respectively.  The government has told Vitas it intends to consolidate these cases with the 2013 Action described below.
 
In June 2012, VITAS received an administrative subpoena from OIG in connection with an investigation of possible improper claims submitted to the Medicare and Medicaid programs.  It seeks production of various categories of documents concerning the provision of hospice services, for headquarters and its Southern California programs, for the period January 1, 2007 through the date of the subpoena.  The categories of documents include policy, procedure and training manuals; documents concerning patient eligibility for hospice care, including referrals, admissions, certifications, revocations and census information; documents concerning claims submitted to government programs; certain information concerning employees and their compensation; and documents concerning VITAS’s financial performance.  In August 2012, the OIG also subpoenaed medical records for 268 patients from three Southern California programs.
 
In September 2012, VITAS received an administrative subpoena from OIG seeking production of medical records for 102 patients in 10 states who received continuous care between 2004 and 2009.  In December 2012, it received a second such administrative subpoena from the OIG seeking medical records for 103 patients who received continuous care between 2009 and 2012.

On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiaries in the U.S. District Court for the Western District of Missouri, United States v. VITAS Hospice Services, LLC, et al., 4:13-cv-00449-BCW (the “2013 Action”).  The 2013 Action alleges that, since at least 2002, VITAS, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for continuous home care services when the patients were not eligible, the services were not provided, or the medical care was inappropriate, and (b) billing Medicare for patients who were not eligible for the Medicare hospice benefit because they did not have a life expectancy of six months or less if their illnesses ran their normal course.  This complaint seeks treble damages, statutory penalties, and the costs of the action, plus interest.
 
On May 6, 2013, the U.S. District Court for the Western District of Missouri, at the request of the government, unsealed a qui tam complaint against VITAS and VITAS Healthcare Corporation of California, United States ex rel. Charles Gonzales v. Vitas Healthcare Corporation, et al., CV 12-0761-R (“Gonzales”).  The case was transferred from the Central District of California to the Western District of Missouri under docket No. 4:13-cv-344.  The government has filed a notice of election to intervene in the Gonzales complaint.  The Gonzales complaint alleges that VITAS’ Los Angeles program falsely certified and recertified patients as eligible for the Medicare Hospice Benefit.  It alleges violations of the False Claims Act and seeks treble damages, civil penalties, recovery of costs, attorneys’ fees and expenses, and pre- and post-judgment interest.   In its notice of election to intervene in Gonzales, the government stated that it intends to seek to consolidate the 2013 Action with Gonzales as a related matter. Upon consolidation, the government stated that the complaint in the 2013 Action will supersede the Gonzales complaint.

 
- 21 -

 
 
The Company intends to defend vigorously against the allegations in each of the above lawsuits.  The costs to comply with these investigations were $996,000 and $2.0 million for the three and six month periods ended June 30, 2013.  Regardless of the outcome of any of the preceding matters, responding to the subpoenas and dealing with the various regulatory agencies can adversely affect us through defense costs, diversion of management time, and related publicity.

Results of Operations
Three months ended June 30, 2013 versus  2012 - Consolidated Results
Our service revenues and sales for the second quarter of 2013 increased 0.9% versus services and sales revenues for the second quarter of 2012.  Of this increase, $4.6 million was attributable to Roto-Rooter offset by a $1.6 million decrease at VITAS.  The following chart shows the components of those changes (in thousands):

   
Increase/(Decrease)
 
   
Amount
   
Percent
 
VITAS
            
Routine homecare
 
$
 7,123
   
 3.7
 
Continuous care
   
 (4,555
)  
 (10.6
General inpatient
   
 (3,358
) 
 (11.5
Medicare cap
   
 (855
) 
-
 
Roto-Rooter
            
Plumbing
   
 1,421
   
 3.4
 
Drain cleaning
   
 2,791
   
 8.3
 
Contractor operations
   
 1,345
   
 19.8
 
HVAC operations
   
 (577
) 
 (100.0
Other
   
 (307
) 
 (5.5
Total
 
$
 3,028
   
 0.9
 
 
The decrease in VITAS’ revenues for the second quarter of 2013 versus the second quarter of 2012 was a combination of Medicare reimbursement rates declining approximately 1.1%, increased ADC of 4.0%, and level of care mix shift.  In the second quarter of 2013, VITAS recorded a Medicare Cap charge of $855,000 related to one program’s projected 2013 Medicare Cap liability.  This compares with no Medicare Cap liability recorded in the second quarter of 2012.  The ADC increase was driven by a 5.0% increase in routine homecare, a decrease of 8.6% in continuous care and a decrease of 6.9% in general inpatient.  In excess of 90% of VITAS’ service revenues for the period were from Medicare and Medicaid.
 
The increase in plumbing revenues for the second quarter of 2013 versus 2012 is attributable to a 1.1% decrease in job count offset by a 4.5% increase in price and mix shift.  Drain cleaning revenues for the second quarter of 2013 versus 2012 reflect a 4.8% increase in the number of jobs perfomed as well as a 3.5% increase in price and mix shift.  Contractor operations revenue increased 19.8% for the second quarter of 2013 due to four acquisitions that were completed in 2012 as well as improved operating conditions.  HVAC operations decreased as a result of the shut-down of Roto-Rooter’s one remaining HVAC operation during the third quarter of 2012.
 
The consolidated gross margin was 28.5% in the second quarter of 2013 as compared with 27.3% in the second quarter of 2012.  On a segment basis, VITAS’ gross margin was 21.9% in the second quarter of 2013 and 21.6% in the second quarter of 2012.  The Roto-Rooter segment’s gross margin was 47.1% for the second quarter of 2013 as compared with 44.3% for the second quarter of 2012.  The increase in Roto-Rooter’s gross margin is the result of higher revenue, lower health care and casualty insurance costs and reduced field operating expenses.
 
 
- 22 -

 
 
Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

   Three months ended June 30, 
   
2013
  
2012
 
SG&A expenses before the impact of market gains of deferred compensation
      
plans, long-term incentive compensation, and OIG investigation expenses
 $50,554  $50,523 
Long-term incentive compensation
  494   - 
Expenses related to OIG investigation
  996   195 
Impact of market value gains/(losses) on liabilities held in
        
deferred compensation trusts
  1,063   (948)
Total SG&A expenses
 $53,107  $49,770 
 
SG&A expenses before long-term incentive compensation, expenses related to OIG investigation and the impact of market gains of deferred compensation plans for the second quarter of 2013 were essentially flat when compared to the second quarter of 2012.

Other income - net comprise (in thousands):
        
   
Three months ended June 30,
 
   
2013
  
2012
 
Market value gains/(losses) on assets held in deferred
      
compensation trusts
 $1,063  $(948)
Loss on disposal of property and equipment
  (1)  (67)
Interest income
  670   59 
Other
  (36)  (14)
Total other income/(expense) - net
 $1,696  $(970)

Our effective income tax rate was 38.9% in the second quarter of 2013 essentially flat with the second quarter of 2012.

Net income for both periods included the following after-tax items/adjustments that reduced after-tax earnings (in thousands):
        
   
Three months ended June 30,
 
   
2013
  
2012
 
VITAS
      
Legal expenses of OIG investigation
 $(618) $(121)
Acquisition expenses
  (12)  - 
Roto-Rooter
        
Litigation settlement
  (8,967)  - 
Expenses related to litigation settlements
  (344)  (49)
Acquisition expenses
  (1)  (12)
Corporate
        
Stock option expense
  (1,020)  (1,502)
Noncash impact of change in accounting for convertible debt
  (1,348)  (1,248)
Long-term incentive compensation
  (313)  - 
Expenses related to securities litigation
  (1)  (124)
Total
 $(12,624) $(3,056)
 
 
- 23 -

 

Three months ended June 30, 2013 versus 2012 - Segment Results

The change in after-tax earnings for the second quarter of 2013 versus the second quarter of 2012 is due to (in thousands):
     
 
Increase/(Decrease)
 
 
Amount
  
Percent
 
VITAS
 $52   0.3 
Roto-Rooter
  (6,660)  (82.5)
Corporate
  (58)  (0.8)
   $(6,666)  (31.3)

Results of Operations
Six months ended June 30, 2013 versus  2012 - Consolidated Results
Our service revenues and sales for the first six months of 2013 increased 2.4% versus services and sales revenues for the first six months of 2012.  Of this increase, $8.8 million was attributable to VITAS and $7.9 million was attributable to Roto-Rooter.  The following chart shows the components of those changes (in thousands):
 
   
Increase/(Decrease)
 
   
Amount
   
Percent
 
VITAS
            
Routine homecare
 
$
 17,187
   
 4.5
 
Continuous care
   
 (1,751
 
 (2.1
General inpatient
   
 (4,042
 
 (6.9
Medicare cap
   
 (2,559
 
 (99.3
Roto-Rooter
            
Plumbing
   
 1,030
   
 1.2
 
Drain cleaning
   
 5,397
   
 7.9
 
Contractor operations
   
 2,873
   
 21.3
 
HVAC operations
   
 (1,122
 
 (100.0
Other
   
 (287
 
 (2.5
Total
 
$
 16,726
   
 2.4
 

The increase in VITAS’ revenues for the first six months of 2013 versus the first six months of 2012 is a result of, increased ADC of 4.7%, a Medicare reimbursement rate decrease and level of care mix shift.  In the first six months, VITAS recorded a net Medicare Cap reversal of $18,000 related to eliminating the Medicare Cap billing limitation recorded in the fourth quarter of 2012 offset by one programs’ projected 2013 Medicare Cap liability.  This compares to $2.6 million of additional revenue recorded in the first six months of 2012.  The ADC increase was driven by a 5.2% increase in routine homecare, a decrease of 0.6% in continuous care and a decrease of 3.8% in general inpatient.  In excess of 90% of VITAS’ service revenues for the period were from Medicare and Medicaid.

The increase in plumbing revenues for the first six months of 2013 versus 2012 is attributable to a 1.4% decrease in job count offset by a 2.6% increase in price and mix shift.  Drain cleaning revenues for the first six months of 2013 versus 2012 reflect a 4.1% increase in the number of jobs perfomed as well as a 3.8% increase in price and mix shift.  Contractor operations revenue increased 21.3% for the first six months of 2013 due to four acquisitions that were completed in 2012 as well as improved operating conditions.  HVAC operations decreased as a result of the shut-down of Roto-Rooter’s one remaining HVAC operation during the third quarter of 2012.

The consolidated gross margin was 28.2% for the first six months of 2013 as compared with 27.2% in the first six months of 2012.  On a segment basis, VITAS’ gross margin was 21.7% for the first six months of 2013 and 21.4% for the first six months of 2012.  The Roto-Rooter segment’s gross margin was 46.7% for the first six months of 2013 as compared with 44.0% for the first six months of 2012.  The increase in Roto-Rooter’s gross margin is the result of higher revenue, lower health care and casualty insurance costs and reduced field operating expenses.

 
- 24 -

 

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

   
Six months ended June 30,
 
   
2013
  
2012
 
SG&A expenses before long-term incentive
      
compensation and the impact of market gains and
      
losses of deferred compensation plans
 $102,991  $101,486 
Long-term incentive compensation
  1,106   - 
Expenses related to OIG investigation
  2,035   266 
Impact of market value gains on liabilities held in
        
deferred compensation trusts
  2,535   1,185 
Total SG&A expenses
 $108,667  $102,937 

Normal salary increases and revenue related expense increases between periods account for the 1.5% increase in SG&A expenses before long-term incentive compensation, expenses related to OIG investigation and the impact of market gains of deferred compensation plans.

Interest expense for the first six months of 2013 increased 6.9% when compared to the first six months of  2012 as a result of the increase in amortization of  bond discount expense and the loss on extinguishment of debt resulting from the replacement of the previous Credit Agreement in January 2013.

Other income - net comprise (in thousands):

   
Six months ended June 30,
 
   
2013
  
2012
 
Market value gains on assets held in deferred
      
compensation trusts
 $2,535  $1,185 
Loss on disposal of property and equipment
  (79)  (148)
Interest income
  973   110 
Other
  (27)  (22)
Total other income - net
 $3,402  $1,125 

Our effective income tax rate was 38.9% in the first six months of 2013 essentially flat with the first six months of  2012.
 
Net income for both periods included the following after-tax items/adjustments that reduced after-tax earnings (in thousands):

   
Six Months Ended June 30,
 
   
2013
  
2012
 
VITAS
      
Legal expenses of OIG investigation
 $(1,262) $(165)
Acquisition expenses
  (12)  - 
Roto-Rooter
        
Litigation settlements
  (8,967)  - 
Expenses related to litigation settlements
  (430)  (442)
Acquisition expenses
  (1)  (21)
Expense of severance arrangements
  (184)  - 
Corporate
        
Stock option expense
  (1,963)  (2,727)
Noncash impact of change in accounting for convertible debt
  (2,671)  (2,472)
Long-term incentive compensation
  (700)  - 
Expenses of securities litigation
  (2)  (124)
Loss on extinguishment of debt
  (294)  - 
Total
 $(16,486) $(5,951)
 
 
- 25 -

 
 
Six months ended June 30, 2013 versus 2012 - Segment Results

The change in after-tax earnings for the first six months of 2013 versus the first six months of 2012 is due to (in thousands):

   
Increase/(Decrease)
 
   
Amount
  
Percent
 
VITAS
 $568   1.4 
Roto-Rooter
  (4,531)  (29.1)
Corporate
  (870)  (6.3)
   $(4,833)  (11.6)
 
 
- 26 -

 

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
 
CONSOLIDATING STATEMENT OF INCOME
 
FOR THE THREE MONTHS ENDED JUNE 30, 2013
 
(in thousands)(unaudited)
 
           
         
Chemed
 
   
VITAS
  
Roto-Rooter
  
Corporate
  
Consolidated
 
2013 (a)
            
Service revenues and sales
 $263,568  $93,630  $-  $357,198 
Cost of services provided and goods sold
  205,788   49,571   -   255,359 
Selling, general and administrative expenses
  21,063   25,230   6,814   53,107 
Depreciation
  4,520   2,246   133   6,899 
Amortization
  536   149   496   1,181 
Other operating expenses
  -   14,760   -   14,760 
Total costs and expenses
  231,907   91,956   7,443   331,306 
Income/(loss) from operations
  31,661   1,674   (7,443)  25,892 
Interest expense
  (51)  (97)  (3,549)  (3,697)
Intercompany interest income/(expense)
  866   436   (1,302)  - 
Other income/(expense)—net
  585   34   1,077   1,696 
Income/(expense) before income taxes
  33,061   2,047   (11,217)  23,891 
Income taxes
  (12,576)  (633)  3,926   (9,283)
Net income/(loss)
 $20,485  $1,414  $(7,291) $14,608 
                  
(a) The following amounts are included in net income (in thousands):
 
               
Chemed
 
    
VITAS
   
Roto-Rooter
   
Corporate
  
Consolidated
 
Pretax benefit/(cost):
                
Stock option expense
 $-  $-  $(1,612) $(1,612)
Noncash impact of accounting for convertible debt
  -   -   (2,132)  (2,132)
Long-term incentive compensation
  -   -   (494)  (494)
Litigation settlement
  -   (14,760)  -   (14,760)
Expenses related to litigation settlements
  -   (567)  -   (567)
Expenses related to securities litigation
  -   -   (1)  (1)
Acquisition expenses
  (19)  (1)  -   (20)
Expenses related to OIG investigation
  (996)  -   -   (996)
Total
 $(1,015) $(15,328) $(4,239) $(20,582)
                  
               
Chemed
 
    
VITAS
   
Roto-Rooter
   
Corporate
  
Consolidated
 
After-tax benefit/(cost):
                
Stock option expense
 $-  $-  $(1,020) $(1,020)
Noncash impact of accounting for convertible debt
  -   -   (1,348)  (1,348)
Long-term incentive compensation
  -   -   (313)  (313)
Litigation settlement
  -   (8,967)  -   (8,967)
Expenses related to litigation settlements
  -   (344)  -   (344)
Expenses related to securities litigation
  -   -   (1)  (1)
Acquisition expenses
  (12)  (1)  -   (13)
Expenses related to OIG investigation
  (618)  -   -   (618)
Total
 $(630) $(9,312) $(2,682) $(12,624)
 
 
- 27 -

 

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
 
CONSOLIDATING STATEMENT OF INCOME
 
FOR THE THREE MONTHS ENDED JUNE 30, 2012
 
(in thousands)(unaudited)
 
           
         
Chemed
 
   
VITAS
  
Roto-Rooter
  
Corporate
  
Consolidated
 
2012 (a)
            
Service revenues and sales
 $265,213  $88,957  $-  $354,170 
Cost of services provided and goods sold
  207,839   49,529   -   257,368 
Selling, general and administrative expenses
  20,471   24,372   4,927   49,770 
Depreciation
  4,164   2,085   131   6,380 
Amortization
  488   157   482   1,127 
Total costs and expenses
  232,962   76,143   5,540   314,645 
Income/(loss) from operations
  32,251   12,814   (5,540)  39,525 
Interest expense
  (63)  (107)  (3,502)  (3,672)
Intercompany interest income/(expense)
  812   430   (1,242)  - 
Other income/(expense)—net
  (1)  (33)  (936)  (970)
Income/(expense) before income taxes
  32,999   13,104   (11,220)  34,883 
Income taxes
  (12,566)  (5,030)  3,987   (13,609)
Net income/(loss)
 $20,433  $8,074  $(7,233) $21,274 
                  
           
(a) The following amounts are included in net income (in thousands):
         
                
Chemed
 
   
VITAS
   
Roto-Rooter
   
Corporate
   
Consolidated
 
Pretax benefit/(cost):
                
     Stock option expense
 $-  $-  $(2,374) $(2,374)
     Noncash impact of accounting for convertible debt
  -   -   (1,973)  (1,973)
     Expenses related to securities litigation
  -   -   (197)  (197)
     Expenses related to litigation settlements
  -   (80)  -   (80)
     Acquisition expenses
  -   (20)  -   (20)
     Expenses of OIG investigation
  (195)  -   -   (195)
          Total
 $(195) $(100) $(4,544) $(4,839)
                  
                
Chemed
 
   
VITAS
   
Roto-Rooter
   
Corporate
   
Consolidated
 
After-tax benefit/(cost):
                
     Stock option expense
 $-  $-  $(1,502) $(1,502)
     Noncash impact of accounting for convertible debt
  -   -   (1,248)  (1,248)
     Expenses related to securities litigation
  -   -   (124)  (124)
     Expenses related to litigation settlements
  -   (49)  -   (49)
     Acquisition expenses
  -   (12)  -   (12)
     Expenses of OIG investigation
  (121)  -   -   (121)
          Total
 $(121) $(61) $(2,874) $(3,056)
 
 
- 28 -

 

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
 
CONSOLIDATING STATEMENT OF INCOME
 
FOR THE SIX MONTHS ENDED JUNE 30, 2013
 
(in thousands)(unaudited)
 
           
         
Chemed
 
   
VITAS
  
Roto-Rooter
  
Corporate
  
Consolidated
 
2013 (a)
            
Service revenues and sales
 $534,895  $188,944  $-  $723,839 
Cost of services provided and goods sold
  418,949   100,717   -   519,666 
Selling, general and administrative expenses
  42,667   51,892   14,108   108,667 
Depreciation
  9,033   4,394   267   13,694 
Amortization
  1,026   303   979   2,308 
Other operating expenses
  -   14,760   -   14,760 
Total costs and expenses
  471,675   172,066   15,354   659,095 
Income/(loss) from operations
  63,220   16,878   (15,354)  64,744 
Interest expense
  (97)  (156)  (7,538)  (7,791)
Intercompany interest income/(expense)
  1,709   864   (2,573)  - 
Other income/(expense)—net
  805   34   2,563   3,402 
Income/(expense) before income taxes
  65,637   17,620   (22,902)  60,355 
Income taxes
  (25,009)  (6,582)  8,122   (23,469)
Net income/(loss)
 $40,628  $11,038  $(14,780) $36,886 
                  
          
(a) The following amounts are included in net income (in thousands):
         
               
Chemed
 
   
VITAS
  Roto-Rooter  Corporate  
Consolidated
 
Pretax benefit/(cost):
                
Stock option expense
 $-  $-  $(3,103) $(3,103)
Noncash impact of accounting for convertible debt
  -   -   (4,223)  (4,223)
Long-term incentive compensation
  -   -   (1,106)  (1,106)
Expenses of severance arrangements
  -   (302)  -   (302)
Loss on extinguishment of debt
  -   -   (465)  (465)
Litigation settlement
  -   (14,760)  -   (14,760)
Expenses related to litigation settlements
  -   (708)  -   (708)
Expenses related to securities litigation
  -   -   (3)  (3)
Acquisition expenses
  (20)  (1)  -   (21)
Expenses related to OIG investigation
  (2,035)  -   -   (2,035)
Total
 $(2,055) $(15,771) $(8,900) $(26,726)
                  
               
Chemed
 
   
VITAS
  Roto-Rooter  Corporate  
Consolidated
 
After-tax benefit/(cost):
                
Stock option expense
 $-  $-  $(1,963) $(1,963)
Noncash impact of accounting for convertible debt
  -   -   (2,671)  (2,671)
Long-term incentive compensation
  -   -   (700)  (700)
Expenses of severance arrangements
  -   (184)  -   (184)
Loss on extinguishment of debt
  -   -   (294)  (294)
Litigation settlement
  -   (8,967)  -   (8,967)
Expenses related to litigation settlements
  -   (430)  -   (430)
Expenses related to securities litigation
  -   -   (2)  (2)
Acquisition expenses
  (12)  (1)  -   (13)
Expenses related to OIG investigation
  (1,262)  -   -   (1,262)
Total
 $(1,274) $(9,582) $(5,630) $(16,486)
 
 
- 29 -

 

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
 
CONSOLIDATING STATEMENT OF INCOME
 
FOR THE SIX MONTHS ENDED JUNE 30, 2012
 
(in thousands)(unaudited)
 
          
         
Chemed
 
   
VITAS
  
Roto-Rooter
  
Corporate
  
Consolidated
 
2012 (a)
            
Service revenues and sales
 $526,060  $181,053  $-  $707,113 
Cost of services provided and goods sold
  413,459   101,354   -   514,813 
Selling, general and administrative expenses
  40,219   50,525   12,193   102,937 
Depreciation
  8,188   4,171   262   12,621 
Amortization
  978   311   951   2,240 
Total costs and expenses
  462,844   156,361   13,406   632,611 
Income/(loss) from operations
  63,216   24,692   (13,406)  74,502 
Interest expense
  (126)  (214)  (6,949)  (7,289)
Intercompany interest income/(expense)
  1,566   825   (2,391)  - 
Other income/(expense)—net
  (32)  (54)  1,211   1,125 
Income/(expense) before income taxes
  64,624   25,249   (21,535)  68,338 
Income taxes
  (24,564)  (9,680)  7,625   (26,619)
Net income/(loss)
 $40,060  $15,569  $(13,910) $41,719 
                  
           
(a) The following amounts are included in net income (in thousands):
         
               
Chemed
 
   
VITAS
  
Roto-Rooter
  
Corporate
  
Consolidated
 
Pretax benefit/(cost):
                
     Stock option expense
 $-  $-  $(4,312) $(4,312)
     Noncash impact of accounting for convertible debt
  -   -   (3,908)  (3,908)
     Expenses related to securities litigation
  -   -   (197)  (197)
     Expenses related to litigation settlements
  -   (727)  -   (727)
     Acquisition expenses
  -   (35)  -   (35)
     Expenses related to OIG investigation
  (266)  -   -   (266)
          Total
 $(266) $(762) $(8,417) $(9,445)
                  
               
Chemed
 
   
VITAS
  
Roto-Rooter
  
Corporate
  
Consolidated
 
After-tax benefit/(cost):
 $   $   $   $  
     Stock option expense
  -   -   (2,727)  (2,727)
     Noncash impact of accounting for convertible debt
  -   -   (2,472)  (2,472)
     Expenses related to securities litigation
  -   -   (124)  (124)
     Expenses related to litigation settlements
  -   (442)  -   (442)
     Acquisition expenses
  -   (21)  -   (21)
     Expenses related to OIG investigation
  (165)  -   -   (165)
          Total
 $(165) $(463) $(5,323) $(5,951)

 
- 30 -

 

              
Consolidating Summary and Reconciliation of
Adjusted EBITDA
 
              
Chemed Corporation and Subsidiary Companies
    
(in thousands)
         
Chemed
 
For the three months ended June 30, 2013
VITAS
 
Roto-Rooter
 
Corporate
 
Consolidated
 
              
Net income/(loss)
 $20,485  $1,414  $(7,291) $14,608 
Add/(deduct):
                
Interest expense
  51   97   3,549   3,697 
Income taxes
  12,576   633   (3,926)  9,283 
Depreciation
  4,520   2,246   133   6,899 
Amortization
  536   149   496   1,181 
EBITDA
  38,168   4,539   (7,039)  35,668 
Add/(deduct):
                
Intercompany interest expense/(income)
  (866)  (436)  1,302   - 
Interest income
  (642)  (14)  (14)  (670)
Expenses related to OIG investigation
  996   -   -   996 
Acquisition expenses
  19   1   -   20 
Litigation settlement
  -   14,760   -   14,760 
Expenses related to litigation settlements
  -   567   -   567 
Advertising cost adjustment
  -   (505)  -   (505)
Stock option expense
  -   -   1,612   1,612 
Long-term incentive compensation
  -   -   494   494 
Expenses related to securities litigation
  -   -   1   1 
Adjusted EBITDA
 $37,675  $18,912  $(3,644) $52,943 
                  
              
Chemed
 
For the three months ended June 30, 2012
VITAS
 
Roto-Rooter
 
Corporate
 
Consolidated
 
                  
Net income/(loss)
 $20,433  $8,074  $(7,233) $21,274 
Add/(deduct):
                
Interest expense
  63   107   3,502   3,672 
Income taxes
  12,566   5,030   (3,987)  13,609 
Depreciation
  4,164   2,085   131   6,380 
Amortization
  488   157   482   1,127 
EBITDA
  37,714   15,453   (7,105)  46,062 
Add/(deduct):
                
Intercompany interest expense/(income)
  (812)  (430)  1,242   - 
Interest income
  (42)  (2)  (15)  (59)
Expenses related to OIG investigation
  195   -   -   195 
Acquisition expenses
  -   20   -   20 
Expenses related to litigation settlements
  -   80   -   80 
Advertising cost adjustment
  -   (696)  -   (696)
Stock option expense
  -   -   2,374   2,374 
Expenses related to securities litigation
  -   -   197   197 
Adjusted EBITDA
 $37,055  $14,425  $(3,307) $48,173 
 
 
- 31 -

 
 
              
Consolidating Summary and Reconciliation of
Adjusted EBITDA
 
              
Chemed Corporation and Subsidiary Companies
    
(in thousands)
         
Chemed
 
For the six months ended June 30, 2013
VITAS
 
Roto-Rooter
 
Corporate
 
Consolidated
 
              
Net income/(loss)
 $40,628  $11,038  $(14,780) $36,886 
Add/(deduct):
                
Interest expense
  97   156   7,538   7,791 
Income taxes
  25,009   6,582   (8,122)  23,469 
Depreciation
  9,033   4,394   267   13,694 
Amortization
  1,026   303   979   2,308 
EBITDA
  75,793   22,473   (14,118)  84,148 
Add/(deduct):
                
Intercompany interest expense/(income)
  (1,709)  (864)  2,573   - 
Interest income
  (888)  (56)  (29)  (973)
Expenses related to OIG investigation
  2,035   -   -   2,035 
Acquisition expenses
  20   1   -   21 
Litigation settlement
  -   14,760   -   14,760 
Expenses related to litigation settlements
  -   708   -   708 
Advertising cost adjustment
  -   (974)  -   (974)
Expenses of severance arrangements
  -   302   -   302 
Stock option expense
  -   -   3,103   3,103 
Long-term incentive compensation
  -   -   1,106   1,106 
Expenses related to securities litigation
  -   -   3   3 
Adjusted EBITDA
 $75,251  $36,350  $(7,362) $104,239 
                  
              
Chemed
 
For the six months ended June 30, 2012
VITAS
 
Roto-Rooter
 
Corporate
 
Consolidated
 
                  
Net income/(loss)
 $40,060  $15,569  $(13,910) $41,719 
Add/(deduct):
                
Interest expense
  126   214   6,949   7,289 
Income taxes
  24,564   9,680   (7,625)  26,619 
Depreciation
  8,188   4,171   262   12,621 
Amortization
  978   311   951   2,240 
EBITDA
  73,916   29,945   (13,373)  90,488 
Add/(deduct):
                
Intercompany interest expense/(income)
  (1,566)  (825)  2,391   - 
Interest income
  (72)  (10)  (28)  (110)
Expenses related to OIG investigation
  266   -   -   266 
Acquisition expenses
  -   35   -   35 
Expenses related to litigation settlements
  -   727   -   727 
Advertising cost adjustment
  -   (1,402)  -   (1,402)
Stock option expense
  -   -   4,312   4,312 
Expenses related to securities litigation
  -   -   197   197 
Adjusted EBITDA
 $72,544  $28,470  $(6,501) $94,513 
 
 
- 32 -

 

              
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
 
RECONCILIATION OF ADJUSTED NET INCOME
 
(in thousands, except per share data)(unaudited)
 
              
   
Three Months Ended June 30,
  
Six Months Ended June 30,
 
   
2013
  
2012
  
2013
  
2012
 
Net income as reported
 $14,608  $21,274  $36,886  $41,719 
                  
Add/(deduct) after-tax cost of:
                
Litigation settlement
  8,967   -   8,967   - 
Additional interest expense resulting from the change in
                
in accounting for the conversion feature of the
                
convertible notes
  1,348   1,248   2,671   2,472 
Stock option expense
  1,020   1,502   1,963   2,727 
Expenses of OIG investigation
  618   121   1,262   165 
Expenses related to litigation settlements
  344   49   430   442 
Long-term incentive compensation
  313   -   700   - 
Acquisition expenses
  13   12   13   21 
Expenses related to securities litigation
  1   124   2   124 
Loss on extinguishment of debt
  -   -   294   - 
Severance arrangements
  -   -   184   - 
Adjusted net income
 $27,232  $24,330  $53,372  $47,670 
                  
Earnings Per Share As Reported
                
Net income
 $0.79  $1.12  $1.99  $2.20 
Average number of shares outstanding
  18,606   18,998   18,564   18,976 
Diluted Earnings Per Share As Reported
                
Net income
 $0.77  $1.10  $1.94  $2.16 
Average number of shares outstanding
  18,966   19,369   18,980   19,357 
                  
                  
Adjusted Earnings Per Share
                
Net income
 $1.46  $1.28  $2.88  $2.51 
Average number of shares outstanding
  18,606   18,998   18,564   18,976 
Adjusted Diluted Earnings Per Share
                
Net income
 $1.44  $1.26  $2.81  $2.46 
Average number of shares outstanding
  18,966   19,369   18,980   19,357 
                  
The "Footnotes to Financial Statements" are integral parts of this financial information.
 
 
 
- 33 -

 

              
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
 
OPERATING STATISTICS FOR VITAS SEGMENT
 
(unaudited)
 
              
   
Three Months Ended June 30,
  
Six Months Ended June 30,
 
OPERATING STATISTICS
 
2013
  
2012
  
2013
  
2012
 
Net revenue ($000)
            
Homecare
 $200,273  $193,150  $396,934  $379,747 
Inpatient
  25,889   29,247   54,357   58,399 
Continuous care
  38,261   42,816   83,586   85,337 
Total before Medicare cap allowance
 $264,423  $265,213  $534,877  $523,483 
Medicare cap allowance
  (855)  -   18   2,577 
Total
 $263,568  $265,213  $534,895  $526,060 
Net revenue as a percent of total
                
before Medicare cap allowance
                
Homecare
  75.7 %  72.9 %  74.2 %  72.5 %
Inpatient
  9.8   11.0   10.2   11.2 
Continuous care
  14.5   16.1   15.6   16.3 
Total before Medicare cap allowance
  100.0   100.0   100.0   100.0 
Medicare cap allowance
  (0.3)  -   -   0.5 
Total
  99.7 %  100.0 %  100.0 %  100.5 %
Average daily census (days)
                
Homecare
  10,719   9,971   10,538   9,792 
Nursing home
  2,943   3,036   2,936   3,011 
Routine homecare
  13,662   13,007   13,474   12,803 
Inpatient
  434   466   451   469 
Continuous care
  583   638   631   635 
Total
  14,679   14,111   14,556   13,907 
                  
Total Admissions
  15,721   15,912   32,858   32,234 
Total Discharges
  15,763   15,508   32,622   31,707 
Average length of stay (days)
  84.8   74.0   80.9   78.3 
Median length of stay (days)
  16.0   14.0   14.0   14.0 
ADC by major diagnosis
                
Neurological
  35.5 %  33.6 %  35.1 %  34.0 %
Cancer
  16.9   17.7   16.9   17.8 
Cardio
  12.5   11.6   12.0   11.5 
Respiratory
  7.5   6.7   7.3   6.7 
Other
  27.6   30.4   28.7   30.0 
Total
  100.0 %  100.0 %  100.0 %  100.0 %
Admissions by major diagnosis
                
Neurological
  20.1 %  18.9 %  19.8 %  19.2 %
Cancer
  33.6   33.5   32.3   32.9 
Cardio
  13.2   10.8   12.5   11.3 
Respiratory
  9.1   8.1   9.4   8.5 
Other
  24.0   28.7   26.0   28.1 
Total
  100.0 %  100.0 %  100.0 %  100.0 %
Direct patient care margins
                
Routine homecare
  52.3 %  52.4 %  52.1 %  51.4 %
Inpatient
  3.6   12.7   7.4   13.4 
Continuous care
  14.6   19.7   16.3   19.8 
Homecare margin drivers (dollars per patient day)
                
Labor costs
 $55.04  $54.56  $56.09  $56.13 
Drug costs
  7.55   8.31   7.56   8.32 
Home medical equipment
  6.56   6.78   6.70   6.80 
Medical supplies
  3.13   2.79   3.03   2.77 
Inpatient margin drivers (dollars per patient day)
                
Labor costs
 $346.46  $321.16  $333.15  $317.73 
Continuous care margin drivers (dollars per patient day)
                
Labor costs
 $595.29  $569.98  $591.24  $569.76 
Bad debt expense as a percent of revenues
  0.8 %  0.8 %  0.8 %  0.8 %
Accounts receivable --
                
  Days of revenue outstanding- excluding unapplied Medicare payments
  36.8   35.0  
n.a
  
n.a
 
  Days of revenue outstanding- including unapplied Medicare payments
  20.5   30.6  
n.a
  
n.a
 

 
- 34 -

 
 
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made.  These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements.  Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends.  In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters.  Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved.  Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of a new information, future events or otherwise.

Item 3.                      Quantitative and Qualitative Disclosures about Market Risk
 
Our primary market risk exposure relates to interest rate risk exposure through variable interest rate borrowings.  At June 30, 2013, we had no variable rate debt outstanding.  At June 30, 2013, the fair value of the Notes approximates $199.0 million which have a face value of $187.0 million.

Item 4.                      Controls and Procedures
 
We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report.  Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.  There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION
 
Item 1.                   Legal Proceedings

For information regarding the Company’s legal proceedings, see note 10, Legal and Regulatory Matters, under Part I, Item I of this Quarterly Report on Form 10-Q.

Item 1A.                Risk Factors

There have been no material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

 
- 35 -

 

Item 2.                   Unregistered Sales of Equity Securities and Use of Proceeds

Item 2(c). Purchases of Equity Securities by Issuer and Affiliated Purchasers

The following table shows the activity related to our share repurchase program for the first six months of 2013:

              
              
   
Total Number
  
Weighted Average
  
Cumulative Shares
  
Dollar Amount
 
   
of Shares
  
Price Paid Per
  
Repurchased Under
  
Remaining Under
 
   
Repurchased
  
Share
  
the Program
  
The Program
 
              
February 2011 Program
            
January 1 through January 31, 2013
  -  $-   -  $14,739,197 
February 1 through February 28, 2013
  -   -   -   114,739,197 
March 1 through March 31, 2013
  -   -   -  $114,739,197 
                  
First Quarter Total
  -  $-         
                  
April 1 through April 30, 2013
  -  $-   -  $114,739,197 
May 31 through May 31, 2013
  280,701   65.72   280,701   96,291,009 
June 1 through June 30, 2013
  -   -   280,701  $96,291,009 
                  
Second Quarter Total
  280,701  $65.72         
                  
On February 20, 2013, our Board of Directors authorized an additional $100 million under the February 2011 Repurchase Program.
 

Item 3.                      Defaults Upon Senior Securities

None

Item 4.                      Mine Safety Disclosures

None

Item 5.                      Other Information

None

Item 6.                      Exhibits

Exhibit No.
 
Description
     
31.1
 
Certification by Kevin J. McNamara pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.
     
31.2
 
Certification by David P. Williams pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange  Act of 1934.
     
31.3
 
Certification by Arthur V. Tucker, Jr. pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.
     
32.1
 
Certification by Kevin J. McNamara pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2
 
Certification by David P. Williams pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.3
 
Certification by Arthur V. Tucker, Jr. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS
 
XBRL Instance Document
     
101.SCH
 
XBRL Taxonomy Extension Schema
     
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase
   
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase
   
101.LAB
 
XBRL Taxonomy Extension Label Linkbase
     
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase
 
 
- 36 -

 
 
SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
           
Chemed Corporation
           
(Registrant)
             
             
Dated:
 
July 25, 2013
 
By:
 
/s/ Kevin J. McNamara
           
Kevin J. McNamara
           
(President and Chief Executive Officer)
             
             
Dated:
 
July 25, 2013
 
By:
 
/s/ David P. Williams
           
David P. Williams
           
(Executive Vice President and Chief
Financial Officer)
             
             
Dated:
 
July 25, 2013
 
By:
 
/s/ Arthur V. Tucker, Jr.
           
Arthur V. Tucker, Jr.
           
(Vice President and Controller)
 
 
- 37 -